Gentherm (THRM) 10-K 17 Feb 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Feb. 14, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	THRM
Entity Registrant Name	GENTHERM INCORPORATED
Entity Central Index Key	0000903129
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Common Stock, Shares Outstanding		33,021,536
Entity Shell Company	false
Entity File Number	0-21810
Entity Tax Identification Number	95-4318554
Entity Address, Address Line One	21680 Haggerty Road
Entity Address, City or Town	Northville
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48167
City Area Code	248
Local Phone Number	504-0500
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	MI
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, no par value
Document Transition Report	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Public Float			$ 2,342,097,813
Document Annual Report	true
Auditor Firm Id	42
Auditor Name	ERNST & YOUNG LLP
Auditor Location	Detroit, Michigan
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the proxy statement for the 2022 annual meeting of shareholders are incorporated by reference into Part III of this Annual Report to the extent described herein.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 190,606	$ 268,345
Accounts receivable, net	182,987	211,672
Inventory, net	159,477	122,401
Other current assets	32,775	41,188
Total current assets	565,845	643,606
Property and equipment, net	155,270	152,581
Goodwill	66,033	68,024
Other intangible assets, net	37,554	46,421
Operating lease right-of-use assets	24,387	30,642
Deferred income tax assets	69,630	73,912
Other non-current assets	16,624	7,653
Total assets	935,343	1,022,839
Current Liabilities:
Accounts payable	122,727	116,043
Current lease liabilities	5,669	6,032
Current maturities of long-term debt	2,500	2,500
Other current liabilities	82,193	81,409
Total current liabilities	213,089	205,984
Long-term debt, less current maturities	36,250	189,934
Non-current lease liabilities	19,789	24,233
Pension benefit obligation	6,832	8,163
Other non-current liabilities	5,577	8,194
Total liabilities	281,537	436,508
Common Stock:
No par value; 55,000,000 shares authorized 33,008,185 and 32,921,341 issued and outstanding at December 31, 2021 and December 31, 2020, respectively	118,646	121,073
Paid-in capital	5,866	7,458
Accumulated other comprehensive loss	(36,922)	(14,982)
Accumulated earnings	566,216	472,782
Total shareholders’ equity	653,806	586,331
Total liabilities and shareholders’ equity	$ 935,343	$ 1,022,839

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Common Stock, par value
Common Stock, shares authorized	55,000,000	55,000,000
Common Stock, shares issued	33,008,185	32,921,341
Common Stock, shares outstanding	33,008,185	32,921,341

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Product revenues	$ 1,046,150	$ 913,098	$ 971,684
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of sales	$ 742,519	$ 644,994	$ 683,349
Gross margin	303,631	268,104	288,335
Operating expenses:
Research and development expenses	91,807	81,968	91,033
Reimbursed research and development expenses	(16,593)	(13,928)	(18,557)
Net research and development expenses	75,214	68,040	72,476
Selling, general and administrative expenses	109,554	105,044	118,680
Restructuring expenses	3,857	5,803	12,919
Total operating expenses	188,625	178,887	204,075
Operating income	115,006	89,217	84,260
Interest expense, net	(2,758)	(4,559)	(4,763)
Foreign currency gain (loss)	1,487	(5,439)	2,326
Impairment loss			(21,206)
Net loss on divestitures			(1,587)
Other income	117	2,337	121
Earnings before income tax	113,852	81,556	59,151
Income tax expense	20,418	21,866	10,285
Net income	$ 93,434	$ 59,690	$ 48,866
Basic earnings per share	$ 2.82	$ 1.83	$ 1.48
Diluted earnings per share	$ 2.79	$ 1.81	$ 1.47
Weighted average number of shares – basic	33,085,732	32,666,025	33,120,076
Weighted average number of shares – diluted	33,509,720	33,028,104	33,297,589

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 93,434	$ 59,690	$ 48,866
Other comprehensive (loss) income:
Pension benefit obligations	558	(80)	(1,032)
Foreign currency translation adjustments	(21,551)	27,242	(2,722)
Unrealized (loss) gain on foreign currency derivative securities, net of tax	(952)	211	899
Unrealized gain on commodity derivative securities, net of tax	5
Other comprehensive (loss) income, net of tax	(21,940)	27,373	(2,855)
Comprehensive income	$ 71,494	$ 87,063	$ 46,011

Consolidated Statements of Chan

Consolidated Statements of Changes In Shareholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect of Accounting Change Due to Adoption of ASU	Common Stock	Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Earnings	Accumulated EarningsCumulative Effect of Accounting Change Due to Adoption of ASU
Beginning Balance at Dec. 31, 2018	$ 479,699		$ 140,300	$ 14,934	$ (39,500)	$ 363,965
Beginning Balance (ASU 2016-02) at Dec. 31, 2018		$ 261					$ 261
Beginning Balance (in shares) at Dec. 31, 2018			33,857,000
Net income	48,866					48,866
Other comprehensive income (loss)	(2,855)				(2,855)
Stock compensation, net	21,408		$ 25,490	(4,082)
Stock compensation, net, shares			412,000
Stock repurchase	(63,283)		$ (63,283)
Stock repurchase (in shares)			(1,595,000)
Ending Balance at Dec. 31, 2019	484,096		$ 102,507	10,852	(42,355)	413,092
Ending Balance (in shares) at Dec. 31, 2019			32,674,000
Net income	59,690					59,690
Other comprehensive income (loss)	27,373				27,373
Stock compensation, net	24,264		$ 27,658	(3,394)
Stock compensation, net, shares			493,000
Stock repurchase	(9,092)		$ (9,092)
Stock repurchase (in shares)			(246,000)
Ending Balance at Dec. 31, 2020	$ 586,331		$ 121,073	7,458	(14,982)	472,782
Ending Balance (in shares) at Dec. 31, 2020	32,921,341		32,921,000
Net income	$ 93,434					93,434
Other comprehensive income (loss)	(21,940)				(21,940)
Stock compensation, net	15,981		$ 17,573	(1,592)
Stock compensation, net, shares			327,000
Stock repurchase	(20,000)		$ (20,000)
Stock repurchase (in shares)			(240,000)
Ending Balance at Dec. 31, 2021	$ 653,806		$ 118,646	$ 5,866	$ (36,922)	$ 566,216
Ending Balance (in shares) at Dec. 31, 2021	33,008,185		33,008,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Activities:
Net income	$ 93,434	$ 59,690	$ 48,866
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	38,780	41,114	44,246
Deferred income taxes	(150)	849	(7,743)
Non-cash stock based compensation	14,530	8,829	6,253
Loss on disposition of property and equipment	973	683	462
Gain on sale of patents		(1,978)
Impairment loss			21,206
Net loss on divestitures			1,587
Other	(271)	(748)	1,042
Changes in assets and liabilities:
Accounts receivable, net	25,099	(46,742)	7,154
Inventory	(39,873)	(814)	(3,859)
Other assets	10,307	(11,997)	13,363
Accounts payable	8,166	29,960	(10,253)
Other liabilities	(7,919)	31,849	(3,521)
Net cash provided by operating activities	143,076	110,695	118,803
Investing Activities:
Purchases of property and equipment	(38,468)	(17,219)	(23,729)
Cost of technology investments	(7,557)
Proceeds from the sale of patents and property and equipment	22	2,140	219
Acquisition of business	(2,827)		(14,823)
Acquisition of intangible assets		(3,141)
Proceeds from divestiture of businesses, net			44,173
Net cash (used in) provided by investing activities	(48,830)	(18,220)	5,840
Financing Activities:
Borrowing of debt		201,194	37,812
Repayments of debt	(153,243)	(91,439)	(96,999)
Cash paid for the repurchase of Common Stock	(20,000)	(9,092)	(63,283)
Proceeds from the exercise of Common Stock options	8,279	16,552	16,557
Cash paid for the cancellation of restricted stock	(4,108)	(1,117)	(1,402)
Acquisition contingent consideration payment	(69)	(618)
Cash paid for financing costs			(1,278)
Net cash (used in) provided by financing activities	(169,141)	115,480	(108,593)
Foreign currency effect	(2,844)	7,442	(2,722)
Net (decrease) increase in cash, cash equivalents and restricted cash	(77,739)	215,397	13,328
Cash, cash equivalents and restricted cash at beginning of period	268,345	52,948	39,620
Cash, cash equivalents and restricted cash at end of period	190,606	268,345	52,948
Supplemental disclosure of cash flow information:
Cash paid for taxes	14,857	5,013	11,008
Cash paid for interest	$ 2,378	$ 4,204	$ 4,462

Overview

Overview	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Overview	Note 1 — Overview Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is a global developer, manufacturer and marketer of innovative thermal management technologies for a broad range of heating, cooling and temperature control applications, primarily in the automotive and medical industries. Within the automotive industry, our products provide solutions for passenger climate comfort and convenience, battery thermal management and cell connecting systems. Within the medical industry our products provide patient temperature management solutions. Our automotive products can be found on vehicles manufactured by nearly all the major automotive original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company is also developing a number of new technologies and products that are expected to enable improvements to existing products and to create new product applications for existing and new markets. Impact of COVID-19, Supply Chain Disruptions and Other Matters The COVID-19 pandemic that began around December 2019 introduced significant volatility to the global economy, disrupted supply chains and had a widespread adverse effect on the global automotive industry in the first half of 2020, with various direct and indirect adverse impacts continuing throughout 2021. Beginning in February 2020 and continuing into June 2020, substantially all of the Company’s major OEM and Tier 1 customers temporarily ceased or significantly reduced production as a result of restrictions that were requested or mandated by governmental authorities. As a result, substantially all of our manufacturing facilities either temporarily suspended production or experienced significant reductions in volumes during this period. By the end of the second quarter of 2020, the Company had reopened all of its manufacturing facilities, in line with industry demand, and in accordance with local government requirements. Although global automotive industry production has improved relative to the first half of 2020, production remains below recent historic levels. The lingering impacts of COVID-19 into 2021 has impeded global supply chains, resulted in longer lead times and delays in procuring component parts and raw materials, and resulted in inflationary cost increases in certain raw materials, labor and transportation. These broad-based inflationary impacts have negatively impacted the Company’s financial condition, results of operations and cash flows for the fiscal year ended December 31, 2021. Supply shortages of semiconductor chips and other components have resulted in decreases in global automotive vehicle production and significant volatility in customer vehicle production schedules. The Company's semiconductor suppliers, along with most automotive component supply companies that use semiconductors, including Gentherm, have been unable to fully meet the vehicle production demands of the OEMs due to events which are outside the Company's control, including but not limited to, the COVID-19 pandemic, the global semiconductor shortage, fires at suppliers’ facilities, significant weather events impacting semiconductor supplier facilities in the southern United States, and other extraordinary events. In response to the global supply chain instability and inflationary cost increases the Company has taken several actions to minimize any potential and actual adverse impacts by working with its suppliers and customers to closely monitor the availability of semiconductor microchips and other component parts and raw materials, customer vehicle production schedules and any other supply chain inefficiencies that may arise. The consequences of the pandemic and adverse impact to the global economy continue to evolve. Accordingly, the future adverse impact on our business and financial statements remains subject to significant uncertainty as of the date of this filing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). On February 1, 2019, the Company completed the divestiture of its environmental test equipment business, Cincinnati Sub Zero industrial chamber business (“CSZ-IC”) and on October 1, 2019, the Company completed the divestiture of its remote power generation systems business, Gentherm Global Power Technologies (“GPT”). The Company’s consolidated financial statements herein include the results of CSZ-IC and GPT through their respective dates of divestiture, and are included in the Medical segment. Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20%), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer . Intercompany transactions and balances between consolidated businesses have been eliminated. Use of Estimates In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Segment Reporting The Company has two reportable segments: Automotive Medical The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronic and software systems. The Medical reporting segment is comprised of the results from the patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute care, ambulatory, clinics and home health. Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue- producing transaction, that are collected by the Company from a customer, are excluded from P roduct revenue s . Shipping and handling fees billed to customers are included in P roduct revenues , while costs of shipping and handling are included in C ost of sale s . Automotive Revenues The Company provides production parts to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, an LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from its customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Certain LTAs provide for annual price reductions over the production life of the vehicle. Agreements that are determined to provide customers with purchase option discounts that would not be received without entering into the contract are considered to contain a material right (for example, a discount given to a customer that is incremental to the range of discounts typically given to that class of customer). The material right represents a purchase option that provides the customer with the ability to purchase additional production parts at a set price in the future and is accounted for as a separate performance obligation. Under these circumstances, each transfer of production parts under the LTA requires allocation of the purchase price to the production part and the purchase option. As a practical alternative to estimating the standalone selling price of an option, the Company allocates transaction price to the purchase option by reference to the production part volumes expected to be ordered and the consideration expected to be received over the life of the vehicle program. The production part’s relative standalone selling price observed under the LTA is subtracted from the total amount of consideration expected to be received in exchange for transferring of parts under the current contract and the difference is allocated to the purchase option. Revenue from options containing a material right is recognized when the amounts billed to the customer for production parts transferred, under the LTA, is less than the standalone selling price of those production parts. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on body and blood temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized at the point in time the medical products or equipment is transferred to the customer. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company has no material contract assets or contract liabilities as of December 31, 2021. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year. Total capitalized costs to obtain a contract were $1,946 and $1,805 as of December 31, 2021 and 2020, respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program. During the year ended December 31, 2021 and 2020, $174 and $263, respectively, was amortized into Product revenues. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. Cash balances in individual banks may exceed the federally insured limit by the Federal Deposit Insurance Corporation. The Company had Cash and cash equivalents of $161,496 and $106,598 held in foreign jurisdictions as of December 31, 2021 and 2020, respectively. Restricted cash includes cash that is legally restricted as to use or withdrawal. Disclosures About Fair Value of Financial Instruments The carrying amounts of financial instruments comprising cash and cash equivalents, short-term investments, accounts receivable, notes receivable and accounts payable approximate fair value because of the short maturities of these instruments. The carrying amount of the Company’s revolving credit note under the June 27, 2019 amended and restated credit agreement (“Credit Agreement”) approximates its fair value because interest charged on the loan balance is variable. See Note 14, “Fair Value Measurement,” for information about the techniques used to assess the fair value of financial assets and liabilities, including our fixed rate debt instruments. Concentration of Credit Risk Financial assets, which subject the Company to concentration of credit risk, consist primarily of cash equivalents, short-term investments, accounts receivable and notes receivable. Cash equivalents consist primarily of money market funds managed by major financial services companies. The credit risk for these cash equivalents is considered low. The Company does not require collateral from its customers. As of December 31, 2021, the Company’s Automotive customers, Adient and Lear both individually represented 22% and 18%, respectively, of the Company’s accounts receivable balance. As of December 31, 2020, Adient and Lear both individually represented 18% of the Company’s accounts receivable balance. Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses and historical cash discounts. Primarily in the Asia-Pacific region, the Company receives bank notes from certain customers to settle trade receivables. The collection of such bank notes is included in operating cash flows based on the substance of the underlying transactions, which are operating in nature. Bank notes held by the Company are classified as notes receivable within other current assets. The Company may hold such bank notes until maturity, exchange them with suppliers to settle liabilities, or sell them to third-party financial institutions in exchange for cash. Inventory The Company’s inventory is measured at the lower of cost or net realizable value. Raw materials, components and consumables are measured using the weighted average cost method. Work-in-process and finished goods are measured using the first-in first-out method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve. Property and Equipment Property and equipment, including additions and improvements, are recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as Operating income or expense. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years The Company recognized depreciation expense of $29,622, $31,037 and $33,639 for the years ended December 31, 2021, 2020 and 2019, respectively. Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in Other current assets in the accompanying consolidated balance sheets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2021 and 2020, the Company had $3,778 and $4,831, respectively, of reimbursable tooling costs capitalized. Company-owned tooling is included in Property and equipment and depreciated over its expected useful life, generally two to ten years. Management periodically evaluates the recoverability of tooling costs, based on estimated future cash flows, and makes provisions, where appropriate, for tooling costs that will not be recovered. Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 10 years Product development costs 5 to 10 years Trade names Indefinite Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. Our policy is to expense all costs associated with the development and issuance of new patents as incurred. Such costs are classified as research and development expenses in the accompanying consolidat ed statements of income . Impairments of Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect a risk factor, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount . Investments in non-consolidated affiliates During 2021, the Company’s Automotive segment invested $5,200 for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. During 2021, the Company’s Automotive segment invested $2,357 for an ownership interest in Forciot Oy (“Forciot”), a technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. In December 2021, the Company committed to make a $5,000 investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten year life of the fund. The Company has not made any contributions to the Autotech Fund III, LP as of December 31, 2021. This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy. Research and Development Expenses Research and development activities are expensed as incurred. The Company groups development and prototype costs and related reimbursements in research and development. Leases The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 10 years and may include options to extend the lease. Land leases have remaining lease terms that range from 39 to 41 years and some which specify that the end of the lease term is at the discretion of the lessee. We do not have lease arrangements with related parties. The Company determines whether a contractual arrangement is or contains a lease at inception. Leases that are operating in nature are recognized in Operating lease right-of-use assets, Current lease liabilities and Non-current lease liabilities in the accompanying consolidated balance sheets. Gentherm is not currently party to any leases that qualify as financing leases. Lease liabilities are measured initially at the present value of the sum of the future minimum rental payments at the commencement date of the lease. Lease payments that will vary in the future due to changes in facts and circumstances are excluded from the calculation of rental payments, unless those variable payments are based on an index or rate. Rental payments are discounted using an incremental borrowing rate, unless there is a rate implicit in the lease agreement. The incremental borrowing rate is based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). Judgement is used to assess the importance of risk factor inputs during the computation of the Company’s credit rating. For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease right-of-use assets are measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentive received, and initial direct costs incurred, as applicable. Periods covered by an option to extend the lease are initially included in the measurement of an operating lease right-of-use asset and lease liability only when it is reasonably certain we will exercise the option. Gentherm’s lease agreements do not contain residual value guarantees or impose restrictions or covenants on the Company. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income. Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2021 and 2020, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognize s the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in I ncome tax expense. Derivative Financial Instruments – Hedge Accounting The Company accounts for its derivative financial instruments as cash flow hedges. For derivative contracts which are designated as a cash flow hedge, the effective portion of the change in the fair value of the derivative contract is recorded to Accumulated other comprehensive loss (“AOCI”) in the accompanying consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in AOCI is recorded into earnings in the accompanying consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the accompanying consolidated statements of income under Foreign currency gain (loss) for foreign currency derivatives, and cost of goods sold for commodity derivatives. These hedging transactions and the respective correlations meet the requirements for hedge accounting. Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the respective period. The Company’s diluted earnings per share give effect to all potential shares of common stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of common stock equivalents. Stock Based Compensation Share based payments that involve the issuance of common stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the consolidated financial statements as compensation expense based upon the fair value on the date of grant. Share based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense.

New Accounting Pronouncements

New Accounting Pronouncements	12 Months Ended
	Dec. 31, 2021
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
New Accounting Pronouncements	Note 3 — New Accounting Pronouncements Recently Adopted Accounting Pronouncements Income Taxes In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". This ASU simplifies the accounting for income taxes by removing certain exceptions previously included in the guidance. In addition, the ASU amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 as of January 1, 2021 and there was no significant impact on its financial statements and related disclosures as a result Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting”. ASU 2020-04 provides practical expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments in this update apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued as a result of reference rate reform. These amendments are not applicable to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. In January 2021, the FASB subsequently issued ASU 2021-01, “Reference Rate Reform (Topic 848): Scope” to clarify that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. ASU 2020-04 and ASU 2021-01 are effective as of March 12, 2020 through December 31, 2022 and may be applied retrospectively to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020, or on a prospective basis to new modifications from any date within an interim period that includes or is subsequent to the date of the issuance of a final update, up to the date that financial statements are available to be issued. Upon adoption of this standard, the Company does not expect it to have a material impact to the Company’s financial statements.

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Acquisitions and Divestitures	Note 4 – Acquisitions and Divestitures Acquisition of Beckmann & Egle Industrieelektronik GmbH On July 1, 2021, the Company acquired the medical business unit of Beckmann & Egle Industrieelektronik GmbH (“B&E”), a developer and manufacturer of electronic control units, for a purchase price of $2,827. The acquisition was accounted for as a business combination with the purchase price assigned to inventory, property and equipment and other intangible assets based on their estimated fair values as of the acquisition date. The pro forma effect of the B&E acquisition does not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented. The results of operations of B&E are reported within the Company’s Medical segment from the date of acquisition. Divestiture of GPT On October 1, 2019, the Company completed the sale of GPT for a nominal amount and recognized a $5,885 loss on sale for the year ended December 31, 2019, which is classified as Net loss on divestitures within the consolidated statements of income. During 2019, the Company also recognized impairment losses of $21,206 for its GPT assets held for sale. These impairment charges are classified as Impairment loss within the consolidated statements of income. Acquisition of Stihler Electronic GmbH On April 1, 2019, the Company acquired Stihler Electronic GmbH (“Stihler”), a leading developer and manufacturer of patient and blood temperature management systems, for a purchase price of $15,476, net of cash acquired and including $653 of contingent consideration that was paid upon achievement of a milestone during the year ended December 31, 2020. The results of operations of Stihler are reported within the Company’s Medical segment from the date of acquisition. Divestiture of CSZ-IC On February 1, 2019, the Company completed the sale of its environmental test equipment business, CSZ-IC and former Cincinnati Sub-Zero headquarters facility for total cash proceeds of $47,500. The Company recognized a $4,298 pre-tax gain on the sale of CSZ-IC for the year ended December 31, 2019 which is classified as Net loss on divestitures within the consolidated statements of income.

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2021
Restructuring And Related Activities [Abstract]
Restructuring	Note 5 — Manufacturing Footprint Rationalization In September 2019, the Company committed to a restructuring plan (“Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this Plan, the Company is relocating and consolidating certain automotive electronics manufacturing plants in North America and China. During 2021, the Company completed the closures and relocation of its automotive electronics manufacturing operations from Burlington, Canada to Celaya, Mexico and from Longgang, Shenzhen, China to Bantian, Shenzhen, China. As of December 31, 2021, the electronics manufacturing in Acuña, Mexico continues to transition to Celaya, Mexico. During the year ended December 31, 2021, the Company recognized restructuring expense of $1,303 for employee separation costs and $1,665 for other costs, primarily related to equipment move and set up costs. During the year ended December 31, 2020, the Company recognized restructuring expense of $(832) for employee separation costs and $1,019 for other costs, primarily related to accelerated depreciation and equipment move and set up costs. The net activity for the year ended December 31, 2020 was primarily related to a reduction in the estimates of previously recognized employee separation costs. During the year ended December 31, 2019, the Company recognized restructuring expense of $4,863 for employee separation costs, and $2,087 of other costs, primarily related to accelerated depreciation and fixed asset impairment. The Company has recorded approximately $10,105 of restructuring expenses since the inception of this program and as of December 31, 2021, $943 remains accrued. Actions under the Plan are expected to be substantially completed by the first half of 2022 and future expenses are expected to be less than $1,000. Other Restructuring Activities As part of the Company’s continued efforts to optimize its cost structure, the Company has undertaken several discrete restructuring actions. During the years ended December 31, 2021, 2020 and 2019, the Company recognized $889, $5,382 and $3,193 of employee separation costs, respectively, and $0, $234 and $2,776 of other related costs, respectively. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to best cost locations and the reduction of global overhead costs. Restructuring Expenses By Reporting Segment Restructuring expense by reporting segment for the years ended December 31, 2021, 2020 and 2019 was as follows: Year Ended December 31, 2021 2020 2019 Automotive $ 2,793 $ 5,075 $ 9,353 Medical — 112 1,838 Corporate 1,064 616 1,728 Total $ 3,857 $ 5,803 $ 12,919 Restructuring Liability The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2021 and 2020: Employee Separation Costs Other Related Costs Total Balance at December 31, 2019 $ 5,994 $ 71 $ 6,065 Additions, charged to restructuring expenses 6,932 1,271 8,203 Change in estimate (2,382 ) (18 ) (2,400 ) Cash payments (5,052 ) (757 ) (5,809 ) Non-cash utilization — (687 ) (687 ) Currency translation and other 135 120 255 Balance at December 31, 2020 $ 5,627 $ — $ 5,627 Additions, charged to restructuring expenses 2,406 1,927 4,333 Change in estimate (214 ) (262 ) (476 ) Cash payments (6,129 ) (1,709 ) (7,838 ) Non-cash utilization — (218 ) (218 ) Currency translation and other (196 ) 262 66 Balance at December 31, 2021 $ 1,494 $ — $ 1,494

Details of Certain Financial St

Details of Certain Financial Statement Components	12 Months Ended
	Dec. 31, 2021
Financial Statement Components [Abstract]
Details of Certain Financial Statement Components	Note 6 — Details of Certain Financial Statement Components December 31, 2021 2020 Inventory: Raw materials, net of reserve $ 96,426 $ 68,362 Work in process, net of reserve 9,495 8,247 Finished goods, net of reserve 53,556 45,792 Total inventory, net $ 159,477 $ 122,401 Other current assets: Notes receivable $ 13,033 $ 19,200 Income tax and other tax receivable 10,681 10,514 Billable tooling 3,778 4,831 Prepaid expenses 3,407 3,930 Other 1,876 2,713 Total other current assets $ 32,775 $ 41,188 Property and equipment: Machinery and equipment $ 155,463 $ 142,833 Buildings and improvements 100,788 99,011 Information technology 33,060 30,338 Production tooling 25,180 22,783 Leasehold improvements 11,445 11,762 Construction in progress 14,506 8,968 Total property and equipment 340,442 315,695 Less: accumulated depreciation (185,172 ) (163,114 ) Total property and equipment, net $ 155,270 $ 152,581 Other current liabilities: Accrued employee liabilities $ 28,818 $ 26,612 Liabilities from discounts and rebates 27,343 22,910 Income tax and other taxes payable 17,068 14,714 Restructuring 1,494 5,627 Accrued warranty 1,916 2,391 Other 5,554 9,155 Total other current liabilities $ 82,193 $ 81,409

Goodwill and Other Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	Note 7 — Goodwill and Other Intangibles Goodwill Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2021 and 2020 were as follows: Automotive Medical Total December 31, 2019 $ 36,938 $ 27,634 $ 64,572 Exchange rate impact 2,557 895 3,452 Balance as of December 31, 2020 $ 39,495 $ 28,529 $ 68,024 Acquisition of B&E — 976 976 Exchange rate impact (2,166 ) (801 ) (2,967 ) Balance as of December 31, 2021 $ 37,329 $ 28,704 $ 66,033 Other Intangible Assets Other intangible assets and accumulated amortization balances as of December 31, 2021 and 2020 were as follows: Gross Carrying Value Accumulated Amortization Net Carrying Value Definite-lived: Customer relationships $ 90,448 $ (64,105 ) $ 26,343 Technology 29,464 (24,487 ) 4,977 Product development costs 20,329 (19,772 ) 557 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2021 $ 145,918 $ (108,364 ) $ 37,554 Gross Carrying Value Accumulated Amortization Net Carrying Value Definite-lived: Customer relationships $ 97,815 $ (63,432 ) $ 34,383 Technology 30,615 (24,075 ) 6,540 Product development costs 22,164 (21,336 ) 828 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2020 $ 155,264 $ (108,843 ) $ 46,421 In connection with the acquisition of B&E, the Company recorded technology of $976. These definite-lived assets are being amortized using the straight-line method over their estimated useful lives of approximately seven years. On February 28, 2020, Gentherm acquired the automotive patents and technology of a development-stage technology company for $3,141. The investment was accounted for as an asset acquisition of defensive intangible assets and will be amortized over six years. On June 19, 2020, Gentherm sold patents from a non-core business for $2,055. The gain on sale of $1,978 was recorded in Other income in the consolidated statements of income. A total of $8,821, $9,226 and $10,068 in other intangible assets were amortized in 2021, 2020 and 2019, respectively. An estimate of other intangible asset amortization by year, is as follows: 2022 $ 7,929 2023 $ 4,752 2024 $ 3,692 2025 $ 3,678 2026 $ 3,261

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	Note 8 — Leases Components of lease expense for the years ended December Year Ended December 31, 2021 2020 2019 Lease cost: Operating lease cost $ 8,227 $ 6,773 $ 5,899 Short-term lease cost 1,941 1,834 3,444 Sublease income (163 ) (158 ) (128 ) Total lease cost $ 10,005 $ 8,449 $ 9,215 Other information related to leases is as follows: Year Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 7,685 $ 6,817 Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 2,379 $ 25,161 December 31, 2021 December 31, 2020 Weighted average remaining lease term: Operating leases 6.9 years 5.4 years Weighted average discount rate: Operating leases 4.53 % 4.65 % A summary of operating leases as of December 31, 2021, under all non-cancellable operating leases with terms exceeding one year is as follows: . 2022 $ 6,541 2023 4,664 2024 4,200 2025 3,783 2026 2,945 2027 or later 7,538 Total future minimum lease payments 29,671 Less imputed interest (4,213 ) Total $ 25,458

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	Note 9 — The following table summarizes the Company’s debt as of December 31, 2021 and 2020: December 31, 2021 2020 Interest Rate Principal Balance Interest Rate Principal Balance Amended Credit Agreement: U.S. Revolving Note (U.S. Dollar denominations) 1.35 % $ 35,000 1.65 % $ 171,500 U.S. Revolving Note (Euro denominations) — — 1.50 % 14,684 DEG Vietnam Loan 5.21 % 3,750 5.21 % 6,250 Total debt 38,750 192,434 Current maturities (2,500 ) (2,500 ) Long-term debt, less current maturities $ 36,250 $ 189,934 Credit Agreement On June 27, 2019, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent, which includes a revolving credit note (“U.S. Revolving Note”). The Credit Agreement has maximum borrowing capacity of $475,000 and matures on June 27, 2024. The Credit Agreement also provides $15,000 availability for the issuance of letters of credit and a maximum of $40,000 for swing line borrowing. Any amount of the facility utilized for letters of credit or swing line loans outstanding will reduce the amount available under the Credit Agreement. The Company had no outstanding letters of credit issued under the Credit Agreement as of December 31, 2021 and December 31, 2020. The U.S. borrowers and guarantors participating in the Credit Agreement also entered into a related amended and restated pledge and security agreement. The amended and restated pledge and security agreement grants a security interest to the lenders in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Credit Agreement, including the stock and membership interests of specified subsidiaries (limited to 66% of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Credit Agreement are unconditionally guaranteed by certain of the Company’s subsidiaries. The Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders. The Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets, merge with other companies or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and Consolidated Leverage Ratio (based on consolidated EBITDA for the applicable trailing 12-month period as defined in the Credit Agreement) as of the end of any fiscal quarter. The Credit Agreement also contains customary events of default. As of December 31 Under the Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Eurocurrency rate (“Eurocurrency Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate (0.07% at December 31, 2021) plus 0.50%, Bank of America’s prime rate (3.25% at December 31, 2021), or the Eurocurrency rate plus 1.00%. The rate for Eurocurrency Rate Loans denominated in U.S. Dollars is equal to the London Interbank Offered Rate (0.10% at December 31, 2021). All loans denominated in a currency other than the U.S. Dollar must be Eurocurrency Rate Loans. Interest is payable at least quarterly. The Applicable Rate varies based on the Consolidated Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Amended Credit Agreement, the lowest and highest possible Applicable Rate is 1.25% and 2.25%, respectively, for Eurocurrency Rate Loans and 0.25% and 1.25%, respectively, for Base Rate Loans. In March 2020, the Company increased its borrowings under the Credit Agreement by $169,546 as a safeguard to increase its cash position and provide additional financial flexibility due to the COVID-19 pandemic. The proceeds were used for working capital and for other general corporate purposes permitted by the Credit Agreement. As of the end of the first quarter of 2021, the Company repaid the full drawdown of $169,546 from March 2020 under the Credit Agreement. As of December 31, 2021, $35,000 was outstanding under the Credit Agreement. Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and Consolidated Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing twelve months calculated for purposes of the Consolidated Leverage Ratio, $440,000 remained available as of December 31, 2021 for additional borrowings under the Credit Agreement subject to specified conditions that Gentherm currently satisfies. DEG Vietnam Loan The Company also has a fixed interest rate loan with the German Investment Corporation (“DEG”), a subsidiary of KfW Banking Group, a Germany government-owned development bank. The fixed interest rate senior loan agreement with DEG was used to finance the construction and set up of the Vietnam production facility (“DEG Vietnam Loan”). The DEG Vietnam Loan is subject to semi-annual principal payments that began November, 2017 and will end May, 2023. Under the terms of the DEG Vietnam Loan, the Company must maintain a minimum Enhanced Equity Ratio, as defined by the DEG Vietnam Loan agreement, based on the financial statements of Gentherm’s wholly owned subsidiary, Gentherm Vietnam Co. Ltd. As of December 31, 2021, the Company was in compliance with all terms as outlined in the DEG Vietnam Loan. The scheduled principal maturities of our debt as of December 31, 2021 were as follows: DEG Vietnam Note U.S. Revolving Note Total 2022 $ 2,500 $ — $ 2,500 2023 1,250 — 1,250 2024 — 35,000 35,000 Total $ 3,750 $ 35,000 $ 38,750

Pension and Other Post Retireme

Pension and Other Post Retirement Benefit Plans	12 Months Ended
	Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]
Pension and Other Post Retirement Benefit Plans	Note 10 — The Company maintains a U.S. defined benefit pension plan covering its former Chief Executive Officer (“U.S. Plan”) and a German defined benefit pension plan covering certain retired executive employees of the Company’s wholly owned subsidiary, Gentherm GmbH (“German Plan”). The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2021, 2020 and 2019 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2021 2020 2019 2021 2020 2019 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 42 85 127 91 88 147 Expected return on plan assets — — — (120 ) (121 ) (126 ) Amortization of prior service cost and actuarial loss 26 7 — 133 124 72 Net periodic benefit cost $ 68 $ 92 $ 127 $ 104 $ 91 $ 93 Assumptions: Discount rate 1.20 % 2.40 % 3.65 % 1.08 % 1.06 % 1.06 % Long-term return on assets N/A N/A N/A 2.90 % 3.10 % 3.10 % A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2021 and 2020 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2021 2020 2021 2020 Change in projected benefit obligation: Balance at beginning of year $ 3,847 $ 3,871 $ 8,934 $ 8,353 Interest cost 42 85 91 88 Paid pension distributions (342 ) (342 ) (310 ) (294 ) Actuarial (gain) loss (101 ) 233 9 40 Exchange rate impact — — (622 ) 747 Balance at end of year $ 3,446 $ 3,847 $ 8,102 $ 8,934 Change in plan assets: Balance at beginning of year — — 4,276 3,825 Actual return on plan assets — — 98 96 Contributions — — 310 294 Paid pension distributions — — (310 ) (294 ) Exchange rate impact — — (305 ) 355 Balance at end of year $ — $ — $ 4,069 $ 4,276 Underfunded Status $ (3,446 ) $ (3,847 ) $ (4,033 ) $ (4,658 ) Balance sheet classification: Other current liabilities $ (342 ) $ (342 ) $ (306 ) $ — Pension benefit obligation (3,104 ) (3,505 ) (3,727 ) (4,658 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 575 701 3,288 3,644 Assumptions: Discount rate 1.80 % 1.20 % 1.25 % 1.08 % Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2022 are as follows: U.S Plan German Plan Actuarial losses $ 21 $ 124 The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2021 2020 2021 2020 Accumulated benefit obligation $ 3,446 $ 3,847 $ 8,102 $ 8,934 Interest costs are recognized in Selling, general and administrative expenses in the consolidated statements of income and actuarial gains and losses are included the consolidated balance sheet as part of Accumulated other comprehensive loss within shareholders’ equity. Actuarial gains or losses are amortized to Selling, general and administrative expense in the consolidated statements of income based on the average future life of the Plan using the corridor method. Prior service cost is included in Selling, general and administrative expenses in the consolidated statements of income. Plan assets – German Plan Plan assets are comprised of Gentherm GmbH’s pension insurance policies and are pledged to the beneficiaries of the German Plan. A market valuation technique, based on observable underlying insurance charges, is used to determine the fair value of the pension plan assets (Level 2). The expected return on plan assets assumption used to calculate Gentherm GmbH’s pension benefit obligation was determined using actual returns realized on plan assets in the prior year. Contributions We do not expect contributions to be paid to the U.S. Plan or the German Plan during the next fiscal year. The schedule of future expected pension payments is as follows: Projected Pension Benefit Payments Year U.S Plan German Plan 2022 $ 342 $ 306 2023 342 316 2024 342 309 2025 342 301 2026 342 292 2027-2031 1,710 2,988 Total $ 3,420 $ 4,512 Defined contribution plans The Company also sponsors defined contribution plans for eligible employees. On a discretionary basis, the Company matches a portion of the employee contributions and or makes additional discretionary contributions. Gentherm recognized costs of $1,724, $1,275 and $1,384 related to contributions to its defined contribution plans during the years ended December 31, 2021, 2020 and 2019, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 — Legal and other contingencies The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters will not have a material adverse effect on its consolidated results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves. Product Liability and Warranty Matters In the event that the Company’s products fail to perform as expected or result in alleged bodily injury or property damage, our products may subject us to warranty claims and product liability. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims in the future or that it will not incur significant costs to defend such claims. The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including claims already filed by customers, the warranty accrual is adjusted quarterly to reflect management’s best estimate of future claims. The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2021 2020 Balance at beginning of year $ 2,391 $ 4,596 Warranty claims paid (2,164 ) (2,598 ) Warranty expense for products shipped during the current period 1,813 1,223 Adjustments to warranty estimates from prior periods (73 ) (893 ) Adjustments due to currency translation (51 ) 63 Balance at end of year $ 1,916 $ 2,391 Other matters Purchase commitments for materials, supplies, services and capital expenditures, as part of the normal course of business, are generally consistent from year to year. Commitments for capital expenditures as of December 31, 2021 were $5,388. During the year ended December 31, 2021, the Company entered into agreements with various suppliers to reserve the right to purchase certain semiconductor chips over the next 24 months, with volume commitments determined based on our anticipated production requirements. As of December 31, 2021, the Company’s total commitments for these semiconductor chip agreements was $24,457. Such agreements provide the Company with priority access to semiconductor chips as they become available, however, these agreements do not guarantee that our suppliers will meet the timing and quantities requested by Gentherm. All other purchase commitments as of December 31, 2021 were immaterial . Employees Approximately 23% of the Company’s workforce are members of industrial trade unions and are employed under the terms of various labor agreements.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings per Share	Note 12 — The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2021 2020 2019 Net income $ 93,434 $ 59,690 $ 48,866 Basic weighted average shares of Common Stock outstanding 33,085,732 32,666,025 33,120,076 Dilutive effect of stock options, restricted stock awards and restricted stock units 423,988 362,079 177,513 Diluted weighted average shares of Common Stock outstanding 33,509,720 33,028,104 33,297,589 Basic earnings per share $ 2.82 $ 1.83 $ 1.48 Diluted earnings per share $ 2.79 $ 1.81 $ 1.47 The following table represents Common Stock issuable upon the exercise of certain stock options that have been excluded from the diluted earnings calculation because the effect of their inclusion would be anti-dilutive. Year Ended December 31, 2021 2020 2019 Anti-dilutive securities share impact — 12,000 214,000 See Note 17 for information about the Company’s different equity incentive plans.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2021
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Financial Instruments	Note 13 —Financial Instruments Derivative Financial Instruments The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won and Vietnamese Dong. The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The maximum length of time over which the Company hedges its exposure to foreign currency exchange risks and price fluctuations in material commodities is fifteen months. The Company had foreign currency derivative contracts with a notional value of $13,974 and $13,299 and copper commodity swap contracts with a notional value of $309 and $0 outstanding as of December 31, 2021 and 2020, respectively. The principal currency hedged by the Company was the Mexican Peso. The Company does not enter into derivative financial instruments for speculative or trading purposes. The Company’s hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to AOCI in the consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to cost of sales, in the consolidated statements of income. Cash flows associated with derivatives are reported in net cash provided by operating activities in the Company’s Consolidated Statements of Cash Flows. The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term. Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2021 is as follows: Asset Derivatives Liability Derivatives Hedge Designation Fair Value Hierarchy Balance Sheet Location Fair Value Balance Sheet Location Fair Value Net Asset/ (Liabilities) Foreign currency derivatives Cash flow hedge Level 2 Other current assets $ 294 Other current liabilities $ — $ 294 Commodity hedges Cash flow hedge Level 2 Other current assets $ 6 Other current liabilities $ — $ 6 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2020 is as follows: Asset Derivatives Liability Derivatives Hedge Designation Fair Value Hierarchy Balance Sheet Location Fair Value Balance Sheet Location Fair Value Net Asset/ (Liabilities) Foreign currency derivatives Cash flow hedge Level 2 Other current assets $ 1,513 Other current liabilities $ — $ 1,513 Commodity hedges Cash flow hedge Level 2 Other current assets $ — Other current liabilities $ — $ — Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2021 2020 2019 Foreign currency derivatives Cost of sales $ 1,609 $ (1,629 ) $ 1,976 Other comprehensive (loss) income (1,217 ) 272 1,151 Foreign currency loss — (118 ) (46 ) Total foreign currency derivatives $ 392 $ (1,475 ) $ 3,081 Commodity derivatives Cost of sales $ 14 $ — $ — Other comprehensive (loss) income 6 — — Total commodity derivatives $ 20 $ — $ — The Company did not incur any hedge ineffectiveness during the years ended December 31, 2021 and 2020. Accounts Receivable Factoring In June 2021, the Company entered into a receivable factoring arrangement that provides for aggregate purchases of up to $41,300 of specified customer accounts in North America. The receivable factoring arrangement results in true sales of the transferred receivables, which are excluded from amounts reported in the consolidated condensed balance sheets when the receivables are transferred in accordance with ASC 860, "Transfers and Servicing”. As of December 31, 2021, there were no outstanding receivables transferred under the receivable factoring agreement.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurement	Note 14 — Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques: Market : This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Income : This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations. Cost : This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost). The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below: Level 1 : Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 : Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability. Level 3 : Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Items Measured at Fair Value on a Recurring Basis Except for derivative financial instruments (see Note 13) and pension plan assets (see Note 10), the Company has no material financial assets and liabilities that are carried at fair value at December 31, 2021 and 2020. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value. Items Measured at Fair Value on a Nonrecurring Basis The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. On July 1, the Company acquired B&E for $2,827. The purchase price was allocated to inventory (Level 2), property and equipment (Level 2) and other intangible assets (Level 3) based on their estimated fair values as of the acquisition date. As of December 31, 2021, and December 31, 2020, there were no other significant assets or liabilities measured at fair value on a non-recurring basis. Items Not Carried at Fair Value The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of December 31, 2021, and 2020, the carrying values of the indebtedness under the Company’s Credit Agreement were not materially different than their estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 9). Discount rates used to measure the fair value of Gentherm’s DEG Vietnam Loan are based on quoted swap rates. As of December 31, 2021, the carrying value of the DEG Vietnam Loan was $3,750, as compared to an estimated fair value of $3,778. As of December 31, 2020, the carrying value of the DEG Vietnam Loan was $6,250 as compared to an estimated fair value of $6,360.

Equity

Equity	12 Months Ended
	Dec. 31, 2021
Stockholders Equity Note [Abstract]
Equity	Note 15 — Equity Common Stock The Company is authorized to issue up to 59,991,000 shares, of which 55,000,000 shares shall be common stock, without par value, and 4,991,000 shall be Preferred Stock, without par value. As of December 31, 2021, an aggregate of 33,008,185 shares of its common stock were issued and outstanding. As of December 31, 2021, there are no preferred stock shares issued or outstanding. The Company’s common stock is listed on the Nasdaq Global Select Market under the symbol, “THRM”, and has the following rights and privileges: ▪ Voting rights. All shares of the Company’s common stock have identical rights and privileges. With limited exceptions, holders of common stock are entitled to one vote for each outstanding share of common stock held of record by each shareholder on all matters properly submitted for the vote of the Company’s shareholders. ▪ Dividend rights . Subject to applicable law, any contractual restrictions and the rights of the holders of outstanding preferred stock, if any, holders of common stock are entitled to receive ratably such dividends and other distributions that the Company’s Board of Directors, in its discretion, declares from time to time. ▪ Liquidation rights . Upon the dissolution, liquidation or winding up of the Company, subject to the rights of the holders of outstanding preferred stock, if any, holders of common stock are entitled to receive ratably the assets of the Company available for distribution to the Company’s shareholders in proportion to the number of shares of common stock held by each shareholder. ▪ Conversion, Redemption and Preemptive Rights . Holders of common stock have no conversion, redemption, sinking fund, preemptive, subscription or similar rights. Stock Repurchase Program In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”) to commence upon expiration of the prior stock repurchase program on December 15, 2020. Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150,000 of its issued and outstanding common stock over a three-year Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the year ended December 31, 2021, the Company repurchased approximately $20,000 of shares under the 2020 Stock Repurchase Program with an average price paid per share of $83.44. The 2020 Stock Repurchase Program had $130,000 repurchase authorization remaining as of December 31, 2021.

Reclassifications Out of Accumu

Reclassifications Out of Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Reclassifications Out of Accumulated Other Comprehensive Income (Loss)	N ote 16 – Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the years ended December 31, 2021, 2020 and 2019 are as follows: Defined Benefit Pension Plans Foreign Currency Translation Adjustments Commodity Hedge Derivatives Foreign Currency Hedge Derivatives Total Balance at December 31, 2020 $ (3,451 ) $ (12,637 ) $ — $ 1,106 $ (14,982 ) Other comprehensive income (loss) before reclassifications 512 (21,274 ) 20 392 (20,350 ) Income tax effect of other comprehensive income (loss) before reclassifications (71 ) (277 ) (4 ) (85 ) (437 ) Amounts reclassified from accumulated other comprehensive loss into net income 159 — (14 ) a (1,609 ) a (1,464 ) Income taxes reclassified into net income (42 ) — 3 350 311 Net current period other comprehensive income (loss) 558 (21,551 ) 5 (952 ) (21,940 ) Balance at December 31, 2021 $ (2,893 ) $ (34,188 ) $ 5 $ 154 $ (36,922 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. Defined Benefit Pension Plans Foreign Currency Translation Adjustments Foreign Currency Hedge Derivatives Total Balance at December 31, 2019 $ (3,371 ) $ (39,879 ) $ 895 $ (42,355 ) Other comprehensive (loss) income before reclassifications (328 ) 27,147 (1,751 ) 25,068 Income tax effect of other comprehensive (loss) income before reclassifications 117 95 381 593 Amounts reclassified from accumulated other comprehensive loss into net income 131 — 2,023 a 2,154 Income taxes reclassified into net income — — (442 ) (442 ) Net current period other comprehensive (loss) income (80 ) 27,242 211 27,373 Balance at December 31, 2020 $ (3,451 ) $ (12,637 ) $ 1,106 $ (14,982 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. Defined Benefit Pension Plans Foreign Currency Translation Adjustments Foreign Currency Hedge Derivatives Total Balance at December 31, 2018 $ (2,339 ) $ (37,157 ) $ (4 ) $ (39,500 ) Other comprehensive (loss) income before reclassifications (1,264 ) (2,329 ) 2,259 (1,334 ) Income tax effect of other comprehensive (loss) income before reclassifications 232 (393 ) (493 ) (654 ) Amounts reclassified from accumulated other comprehensive loss into net income — — (1,108 ) a (1,108 ) Income taxes reclassified into net income — — 241 241 Net current period other comprehensive (loss) income (1,032 ) (2,722 ) 899 (2,855 ) Balance at December 31, 2019 $ (3,371 ) $ (39,879 ) $ 895 $ (42,355 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. We expect all of the existing gains and losses related to foreign currency and commodity derivatives reported in Accumulated other comprehensive income (loss) as of December 31, 2021 to be reclassified into earnings during the twelve-month period ending December 31, 2022.

Accounting for Stock Based Comp

Accounting for Stock Based Compensation	12 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Accounting for Stock Based Compensation	Note 17 — On May 16, 2013, the Compensation Committee of the Company’s Board of Directors (the “Board”) approved the Gentherm Incorporated 2013 Equity Incentive Plan (the “2013 Plan”), covering 3,500,000 shares of our Common Stock. The 2013 Plan was amended on May 19, 2017 to increase the number of available shares by 2,000,000 and further amended on May 21, 2020 to increase the number of available shares by 2,450,000. The 2013 Plan permits the granting of various awards including stock options (including both nonqualified options and incentive options), stock appreciation rights (“SARs”), restricted stock and restricted stock units (“RSUs”), performance-based restricted stock units (“PSUs”) shares and certain other awards to employees, outside directors and consultants and advisors of the Company. As of December 31, 2021, the Company had an aggregate of 2,739,534 shares of Common Stock available to issue under the 2013 Plan. All equity plans are administered by the Compensation Committee of the Board. During the three-year period ended December 31, 2021, the Company has outstanding stock options, SARs, restricted stock awards and restricted stock units to employees, directors and consultants. These awards become available to the recipient upon the satisfaction of a vesting condition, either based on a period of service or based on the performance of a specific achievement. For equity-based awards with a service condition, the requisite service period typically ranges between three to four years for employees and consultants and one year for directors. As of December 31, 2021, there were 319,336 PSUs outstanding. These awards cliff vest after three-years three-year Under FASB ASC Topic 718, the provisions of the PSUs that vest upon the achievement of relative TSR are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this portion award. A third party was engaged to complete a Monte Carlo simulation to account for the market condition. That simulation takes into account the beginning stock price of our common stock, the expected volatilities for the relative TSR comparator group, the expected volatilities for the Company’s stock price, correlation coefficients, the expected risk-free rate of return and the expected dividend yield of the Company and the comparator group. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the relative TSR feature. The grant date fair value of the other PSUs and RSUs are calculated as the closing price of our common stock as quoted on Nasdaq on the grant date multiplied by the number of shares subject to the award. Each of ROIC and Adjusted EBITDA is considered a performance condition and the grant-date fair value for ROIC PSUs and Adjusted EBITDA PSUs corresponds with management's expectation of the probable outcome of the performance condition as of the grant date. The total recognized and unrecognized stock-based compensation expense is as follows: Stock-Based Compensation Expense 2021 2020 2019 Unrecognized Stock-Based Compensation Expense at December 31, 2021 Options $ 482 $ 836 $ 885 $ - Restricted Shares 1,198 1,495 1,600 309 Restricted Stock Units 4,594 3,137 1,751 7,423 Performance Based Units 5,535 3,361 2,017 8,572 Stock Appreciation Rights 2,721 5,494 2,336 - Total Stock-Based Compensation $ 14,530 $ 14,323 $ 8,589 $ 16,304 The related deferred tax benefit for the years ended December 31, 2021, 2020 and 2019 was $2,725, $3,002, and $1,573, respectively. If Gentherm were to realize expired share-based payment arrangements, they would be reported as a forfeit in the activity roll forward tables below. Stock Options The following table summarizes stock option activity during the years ended December 31, 2021, 2020 and 2019: Options Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2018 1,653,000 $ 38.53 4.28 $ 3,610 Granted — — Exercised (428,250 ) 38.66 Forfeited (355,750 ) 39.99 Outstanding at December 31, 2019 869,000 $ 37.87 3.51 $ 5,172 Granted — — Exercised (434,250 ) 38.12 Forfeited (6,750 ) 38.05 Outstanding at December 31, 2020 428,000 $ 37.61 3.20 $ 11,815 Granted — — Exercised (215,250 ) 38.46 Forfeited (6,000 ) 38.05 Outstanding at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375 Exercisable at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375 There have been no stock options granted since the year ended December 31, 2017 and all options are currently vested. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $8,269, $5,317 and $1,681, respectively. Restricted Stock The following table summarizes restricted stock activity during the years ended December 31, 2021, 2020 and 2019: Unvested Restricted Shares Shares Weighted-Average Grant Date Fair Value Outstanding at December 31, 2018 136,566 $ 37.16 Granted 19,920 40.16 Vested (91,566 ) 37.09 Forfeited (30,000 ) 38.05 Outstanding at December 31, 2019 34,920 $ 38.31 Granted 32,406 39.96 Vested (32,420 ) 38.33 Forfeited — — Outstanding at December 31, 2020 34,906 $ 39.82 Granted 13,742 70.18 Vested (37,272 ) 41.70 Forfeited — — Outstanding at December 31, 2021 11,376 $ 70.33 The compensation cost associated with restricted shares is estimated on the date of grant using quoted market prices (Level 1 input). The total fair value of restricted shares vested in 2021, 2020 and 2019 was $1,554, $1,499 and $3,697, respectively. RSUs The following table summarizes restricted stock unit activity during the years ended December 31, 2021, 2020 and 2019: Unvested Restricted Stock Units Time Vesting Shares Weighted-Average Grant Date Fair Value Outstanding at December 31, 2018 86,392 $ 42.53 Granted 107,391 40.99 Vested (23,956 ) 42.62 Forfeited (28,086 ) 39.88 Outstanding at December 31, 2019 141,741 $ 42.16 Granted 132,864 34.41 Vested (50,953 ) 42.13 Forfeited (14,747 ) 39.16 Outstanding at December 31, 2020 208,905 $ 37.26 Granted 93,539 79.79 Vested (88,296 ) 38.49 Forfeited (20,522 ) 48.76 Outstanding at December 31, 2021 193,626 $ 56.02 The total intrinsic value of restricted stock units vested during the years ended December 31, 2021, 2020 and 2019 was $3,398, $2,214 and $1,000, respectively. PSUs The following table summarizes performance stock unit activity during the years ended December 31, 2021, 2020 and 2019: Unvested Performance Stock Units Relative TSR Target Shares Weighted-Average Grant Date Fair Value ROIC Target Shares Weighted-Average Grant Date Fair Value Adjusted EBITDA Target Shares Weighted-Average Grant Date Fair Value Total Outstanding at December 31, 2018 64,785 $ 62.45 64,792 $ 42.53 — $ — 129,577 Granted 56,380 57.39 56,375 41.51 — — 112,755 Vested — — — — — — — Forfeited (26,124 ) 53.98 (26,128 ) 39.41 — — (52,252 ) Outstanding at December 31, 2019 95,041 $ 61.77 95,039 $ 42.78 — $ — 190,080 Granted 77,967 49.25 77,967 33.72 — — 155,934 Vested — — — — — — — Forfeited (15,090 ) 56.84 (15,090 ) 39.96 — — (30,180 ) Outstanding at December 31, 2020 157,918 $ 56.06 157,916 $ 38.58 — $ — 315,834 Granted 20,626 118.08 40,580 78.98 39,930 79.49 101,136 Performance Adjustment 30,828 69.18 (30,830 ) 44.92 — — (2 ) Vested (61,656 ) 69.18 — — — — (61,656 ) Forfeited (16,148 ) 61.10 (17,374 ) 44.32 (2,454 ) 79.49 (35,976 ) Outstanding at December 31, 2021 131,568 $ 62.09 150,292 $ 47.52 37,476 $ 79.49 319,336 The total intrinsic value of performance stock units vested during the years ended December 31, 2021, 2020 and 2019 was $4,265, $0 and $0, respectively. SARs The following table summarizes SARs activity during the years ended December 31, 2021, 2020 and 2019: Stock Appreciation Rights Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2018 988,100 $ 40.61 3.57 $ 2,064 Granted — — Exercised (179,500 ) 32.84 Forfeited (254,350 ) 42.63 Outstanding at December 31, 2019 554,250 $ 39.41 2.84 $ 2,981 Granted — — Exercised (342,150 ) 38.22 Forfeited (40,500 ) 44.39 Outstanding at December 31, 2020 171,600 $ 40.60 2.44 $ 4,224 Granted — — Exercised (116,000 ) 40.34 Forfeited — — Outstanding at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544 Exercisable at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544 There have been no SARs granted since the year ended December 31, 2017 and all SARs are currently vested. The total intrinsic value of SARs exercised during the years ended December 31, 2021, 2020 and 2019 was $4,301, $4,164 and $1,588, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 18 — The income tax provisions were calculated based upon the following components of earnings before income tax for the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Earnings before income tax: Domestic $ (4,547 ) $ (11,374 ) $ 74,531 Foreign 118,399 92,930 (15,380 ) Earnings before income tax $ 113,852 $ 81,556 $ 59,151 The components of the provision for income taxes for the years ended December 31, 2021, 2020 and 2019 are summarized as follows: Year Ended December 31, 2021 2020 2019 Current income tax expense: Federal $ 1,944 $ 784 $ 262 State and local 234 83 94 Foreign 18,390 20,150 17,672 Total current income tax expense $ 20,568 21,017 18,028 Deferred income tax (benefit) expense: Federal (4,400 ) (2,302 ) (2,490 ) State and local (91 ) 32 (1 ) Foreign 4,341 3,119 (5,252 ) Total deferred (benefit) income tax expense (150 ) 849 (7,743 ) Total income tax expense $ 20,418 $ 21,866 $ 10,285 As of December 31, 2021, deferred U.S. income taxes have not been provided on the undistributed earnings of the Company’s foreign subsidiaries since these earnings will not be taxable upon repatriation to the United States. These earnings will be primarily treated as previously taxed income from either the one-time transition tax or global intangible low-taxed income (“GILTI”) provision, or they will be offset with a 100% dividend received deduction. However, the Company continues to provide a deferred tax liability for foreign income and withholding tax that will be incurred with respect to the undistributed foreign earnings that are not indefinitely reinvested. The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2021 and 2020: December 31, 2021 2020 Deferred tax assets: Net operating losses $ 25,610 $ 22,658 Intangible assets 21,179 29,145 Research and development credits 9,736 10,773 Property and equipment 7,071 7,426 Valuation reserves and accrued liabilities 7,333 7,131 Capitalized Research and Development Costs 9,018 Stock compensation 3,832 4,200 Defined benefit obligation 1,466 1,974 Inventory 1,914 1,571 Other credits 10,158 12,068 Unrealized foreign currency exchange loss — 1,431 Other 146 64 Total deferred tax asset 97,463 98,441 Valuation allowance (16,090 ) (17,197 ) Deferred tax liabilities: Unrealized foreign currency exchange gains $ (2,488 ) $ — Undistributed profits of subsidiary (6,676 ) (5,727 ) Property and equipment (2,420 ) (2,758 ) Other (1,428 ) (572 ) Total deferred tax liability (13,012 ) (9,057 ) Net deferred tax asset $ 68,361 $ 72,187 Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2021, 2020 and 2019 are as follows: Year Ended December 31, 2021 2020 2019 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance (1.2 )% (0.4 )% 11.5 % Effect of different tax rates of foreign jurisdictions (5.2 )% (4.7 )% (24.8 )% US taxes on foreign income, net of taxes paid credit 2.0 % 2.5 % 4.3 % Tax credits & deductions related to R&D (2.3 )% (3.8 )% (3.6 )% Non-deductible expenses 1.7 % 2.1 % 3.4 % Other foreign, state and local taxes 1.6 % 1.4 % 1.7 % Tax effects of intercompany transfers 0.6 % 1.4 % 1.5 % Undistributed profit of subsidiaries 1.0 % 0.9 % 1.2 % Stock Option Compensation (2.0 )% (0.4 )% 1.0 % Audit Settlements and Statute Expirations 0.0 % 3.9 % 0.6 % Other 0.7 % 2.9 % (0.4 )% Effective rate 17.9 % 26.8 % 17.4 % The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2021 Years of Expiration U.S. state income tax $ 67,795 2022-2041 Foreign $ 199,153 Never We have NOL carryforwards in various states associated with the benefits of the state dividends received reduction and foreign royalty exclusion. The state NOL carryforwards generally expire at various dates from 2022 to 2041. We have concluded that there is not sufficient evidence these NOL carryforwards will be utilized, and thus have not recognized the benefit of these NOL carryforwards. At December 31, 2021, certain non-U.S. subsidiaries had NOL carryforwards totaling $199,153 which have no expiration date . The Company is subject to taxation in the United States and various state and foreign jurisdictions. As of December 31, 2021, the Company was no longer subject to U.S. Federal examinations by tax authorities for tax years before 2017 and was no longer subject to foreign examinations by tax authorities for tax years before 2014. The Company currently benefits from tax holidays in various non-U.S. jurisdictions with expiration dates from 2024 – 2025. The amount of corporate income tax savings realized by the Company as a result of the tax holidays during the current and prior years was immaterial as a result of operating losses previously generated. At December 31, 2021, 2020 and 2019, the Company had total unrecognized tax benefits of $5,665, $4,967 and $3,795, respectively, all of which, if recognized, would affect the effective income tax rates. The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2021 2020 2019 Balance at beginning of year $ 4,967 $ 3,795 $ 2,819 Additions based on tax position related to current year 1,105 1,489 661 Additions based on tax position related to prior year 160 179 352 Reductions from settlements and statute of limitation expiration (312 ) (650 ) — Effect of foreign currency translation (255 ) 154 (37 ) Balance at end of year $ 5,665 $ 4,967 $ 3,795 The Company classifies income tax-related penalties and net interest as income tax expense. In the years ended December 31, 2021, 2020 and 2019, income tax related interest and penalties were not material. It is reasonably possible that audit settlements, the conclusions of current examinations or the expiration of the statute of limitations in several jurisdictions could impact the Company’s unrecognized tax benefits.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Reporting	Note 19 — Segment information is used by management for making operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss. The Company’s reportable segments are as follows: • Automotive — this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronic and software systems. • Medical — this segment represents the results from our patient temperature management business within the medical industry. The Corporate The tables below present segment information about the reported product revenues and operating income of the Company for years ended December 31, 2021, 2020 and 2019. With the exception of goodwill, asset information by segment is not reported since the Company does not manage assets at a segment level. Automotive Medical Corporate Total 2021: Product revenues $ 1,004,633 $ 41,517 $ — $ 1,046,150 Depreciation and amortization 35,389 2,460 931 38,780 Operating income (loss) 162,994 (1,829 ) (46,159 ) 115,006 2020: Product revenues $ 869,998 $ 43,100 $ — $ 913,098 Depreciation and amortization 37,662 2,366 1,086 41,114 Operating income (loss) 138,410 971 (50,164 ) 89,217 2019: Product revenues $ 920,225 $ 51,459 $ — $ 971,684 Depreciation and amortization 40,923 1,621 1,702 44,246 Operating income (loss) 141,206 (5,735 ) (51,211 ) 84,260 Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2021, 2020 and 2019 are as follows: Year Ended December 31, 2021 2020 2019 Climate Control Seat $ 393,816 $ 342,550 $ 359,355 Seat Heaters 270,054 249,665 284,174 Steering Wheel Heaters 102,496 76,272 65,426 Automotive Cables 84,114 73,997 88,031 Battery Performance Solutions 69,594 50,901 41,498 Electronics 51,648 53,238 47,542 Other Automotive 32,911 23,375 34,199 Subtotal Automotive segment 1,004,633 869,998 920,225 Medical 41,517 43,100 36,860 GPT — — 11,181 CSZ-IC — — 3,418 Subtotal Medical segment 41,517 43,100 51,459 Total Company $ 1,046,150 $ 913,098 $ 971,684 Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2021, 2020 and 2019 is as follows: Year Ended December 31, 2021 2020 2019 United States $ 404,466 $ 377,577 $ 440,316 China 142,816 101,039 71,461 South Korea 93,516 88,745 63,339 Germany 66,929 58,536 81,315 Japan 63,527 57,785 76,197 Romania 51,367 33,147 26,213 Other 223,529 196,269 212,843 Total Non-U.S. 641,684 535,521 531,368 Total Company $ 1,046,150 $ 913,098 $ 971,684 The table below lists the percentage of total product revenues generated from sales to customers which contributed 10% or more to the Company’s total consolidated product revenue for the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Lear 15 % 15 % 16 % Adient 15 % 14 % 15 % Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2021 and 2020 is as follows: December 31, Property and equipment, net 2021 2020 North Macedonia $ 32,682 $ 36,925 China 25,411 20,375 Mexico 20,296 16,034 Vietnam 19,876 21,080 United States 19,222 19,011 Germany 16,174 15,641 Ukraine 9,539 9,034 Hungary 8,995 10,079 Other 3,075 4,402 Total $ 155,270 $ 152,581

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2021
Valuation And Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	GENTHERM INCORPORATED SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS For the Years Ended December 31, 2021, 2020 and 2019 (In thousands) Description Balance at Beginning of Period Charged to Costs and Expenses Other Activity Deductions from Reserves Balance at End of Period Allowance for Doubtful Accounts Year Ended December 31, 2019 $ 851 $ 969 $ (8 ) $ (619 ) $ 1,193 Year Ended December 31, 2020 1,193 1,298 33 (1,363 ) 1,161 Year Ended December 31, 2021 1,161 1,066 (12 ) (816 ) 1,399 Allowance for Deferred Income Tax Assets Year Ended December 31, 2019 $ 9,977 $ 7,830 $ (491 ) $ — $ 17,316 Year Ended December 31, 2020 17,316 — 139 (258 ) 17,197 Year Ended December 31, 2021 17,197 357 (102 ) (1,362 ) 16,090 Reserve for Inventory Year Ended December 31, 2019 $ 6,270 $ 1,679 $ (56 ) $ (1,820 ) $ 6,073 Year Ended December 31, 2020 6,073 1,768 214 (914 ) 7,141 Year Ended December 31, 2021 7,141 2,499 (134 ) (3,492 ) 6,014

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Impact of COVID-19, Supply Chain Disruptions and Other Matters	Impact of COVID-19, Supply Chain Disruptions and Other Matters The COVID-19 pandemic that began around December 2019 introduced significant volatility to the global economy, disrupted supply chains and had a widespread adverse effect on the global automotive industry in the first half of 2020, with various direct and indirect adverse impacts continuing throughout 2021. Beginning in February 2020 and continuing into June 2020, substantially all of the Company’s major OEM and Tier 1 customers temporarily ceased or significantly reduced production as a result of restrictions that were requested or mandated by governmental authorities. As a result, substantially all of our manufacturing facilities either temporarily suspended production or experienced significant reductions in volumes during this period. By the end of the second quarter of 2020, the Company had reopened all of its manufacturing facilities, in line with industry demand, and in accordance with local government requirements. Although global automotive industry production has improved relative to the first half of 2020, production remains below recent historic levels. The lingering impacts of COVID-19 into 2021 has impeded global supply chains, resulted in longer lead times and delays in procuring component parts and raw materials, and resulted in inflationary cost increases in certain raw materials, labor and transportation. These broad-based inflationary impacts have negatively impacted the Company’s financial condition, results of operations and cash flows for the fiscal year ended December 31, 2021. Supply shortages of semiconductor chips and other components have resulted in decreases in global automotive vehicle production and significant volatility in customer vehicle production schedules. The Company's semiconductor suppliers, along with most automotive component supply companies that use semiconductors, including Gentherm, have been unable to fully meet the vehicle production demands of the OEMs due to events which are outside the Company's control, including but not limited to, the COVID-19 pandemic, the global semiconductor shortage, fires at suppliers’ facilities, significant weather events impacting semiconductor supplier facilities in the southern United States, and other extraordinary events. In response to the global supply chain instability and inflationary cost increases the Company has taken several actions to minimize any potential and actual adverse impacts by working with its suppliers and customers to closely monitor the availability of semiconductor microchips and other component parts and raw materials, customer vehicle production schedules and any other supply chain inefficiencies that may arise. The consequences of the pandemic and adverse impact to the global economy continue to evolve. Accordingly, the future adverse impact on our business and financial statements remains subject to significant uncertainty as of the date of this filing.
Basis of Presentation	Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). On February 1, 2019, the Company completed the divestiture of its environmental test equipment business, Cincinnati Sub Zero industrial chamber business (“CSZ-IC”) and on October 1, 2019, the Company completed the divestiture of its remote power generation systems business, Gentherm Global Power Technologies (“GPT”). The Company’s consolidated financial statements herein include the results of CSZ-IC and GPT through their respective dates of divestiture, and are included in the Medical segment.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20%), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer . Intercompany transactions and balances between consolidated businesses have been eliminated.
Use of Estimates	Use of Estimates In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Segment Reporting	Segment Reporting The Company has two reportable segments: Automotive Medical The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronic and software systems. The Medical reporting segment is comprised of the results from the patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute care, ambulatory, clinics and home health.
Revenue Recognition	Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue- producing transaction, that are collected by the Company from a customer, are excluded from P roduct revenue s . Shipping and handling fees billed to customers are included in P roduct revenues , while costs of shipping and handling are included in C ost of sale s . Automotive Revenues The Company provides production parts to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, an LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from its customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Certain LTAs provide for annual price reductions over the production life of the vehicle. Agreements that are determined to provide customers with purchase option discounts that would not be received without entering into the contract are considered to contain a material right (for example, a discount given to a customer that is incremental to the range of discounts typically given to that class of customer). The material right represents a purchase option that provides the customer with the ability to purchase additional production parts at a set price in the future and is accounted for as a separate performance obligation. Under these circumstances, each transfer of production parts under the LTA requires allocation of the purchase price to the production part and the purchase option. As a practical alternative to estimating the standalone selling price of an option, the Company allocates transaction price to the purchase option by reference to the production part volumes expected to be ordered and the consideration expected to be received over the life of the vehicle program. The production part’s relative standalone selling price observed under the LTA is subtracted from the total amount of consideration expected to be received in exchange for transferring of parts under the current contract and the difference is allocated to the purchase option. Revenue from options containing a material right is recognized when the amounts billed to the customer for production parts transferred, under the LTA, is less than the standalone selling price of those production parts. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on body and blood temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized at the point in time the medical products or equipment is transferred to the customer. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company has no material contract assets or contract liabilities as of December 31, 2021. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year. Total capitalized costs to obtain a contract were $1,946 and $1,805 as of December 31, 2021 and 2020, respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program. During the year ended December 31, 2021 and 2020, $174 and $263, respectively, was amortized into Product revenues.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. Cash balances in individual banks may exceed the federally insured limit by the Federal Deposit Insurance Corporation. The Company had Cash and cash equivalents of $161,496 and $106,598 held in foreign jurisdictions as of December 31, 2021 and 2020, respectively. Restricted cash includes cash that is legally restricted as to use or withdrawal.
Disclosures About Fair Value of Financial Instruments	Disclosures About Fair Value of Financial Instruments The carrying amounts of financial instruments comprising cash and cash equivalents, short-term investments, accounts receivable, notes receivable and accounts payable approximate fair value because of the short maturities of these instruments. The carrying amount of the Company’s revolving credit note under the June 27, 2019 amended and restated credit agreement (“Credit Agreement”) approximates its fair value because interest charged on the loan balance is variable. See Note 14, “Fair Value Measurement,” for information about the techniques used to assess the fair value of financial assets and liabilities, including our fixed rate debt instruments.
Concentration of Credit Risk	Concentration of Credit Risk Financial assets, which subject the Company to concentration of credit risk, consist primarily of cash equivalents, short-term investments, accounts receivable and notes receivable. Cash equivalents consist primarily of money market funds managed by major financial services companies. The credit risk for these cash equivalents is considered low. The Company does not require collateral from its customers. As of December 31, 2021, the Company’s Automotive customers, Adient and Lear both individually represented 22% and 18%, respectively, of the Company’s accounts receivable balance. As of December 31, 2020, Adient and Lear both individually represented 18% of the Company’s accounts receivable balance.
Accounts Receivable	Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses and historical cash discounts. Primarily in the Asia-Pacific region, the Company receives bank notes from certain customers to settle trade receivables. The collection of such bank notes is included in operating cash flows based on the substance of the underlying transactions, which are operating in nature. Bank notes held by the Company are classified as notes receivable within other current assets. The Company may hold such bank notes until maturity, exchange them with suppliers to settle liabilities, or sell them to third-party financial institutions in exchange for cash.
Inventory	Inventory The Company’s inventory is measured at the lower of cost or net realizable value. Raw materials, components and consumables are measured using the weighted average cost method. Work-in-process and finished goods are measured using the first-in first-out method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve.
Property and Equipment	Property and Equipment Property and equipment, including additions and improvements, are recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as Operating income or expense. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years The Company recognized depreciation expense of $29,622, $31,037 and $33,639 for the years ended December 31, 2021, 2020 and 2019, respectively.
Tooling	Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in Other current assets in the accompanying consolidated balance sheets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2021 and 2020, the Company had $3,778 and $4,831, respectively, of reimbursable tooling costs capitalized. Company-owned tooling is included in Property and equipment and depreciated over its expected useful life, generally two to ten years. Management periodically evaluates the recoverability of tooling costs, based on estimated future cash flows, and makes provisions, where appropriate, for tooling costs that will not be recovered.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 10 years Product development costs 5 to 10 years Trade names Indefinite Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. Our policy is to expense all costs associated with the development and issuance of new patents as incurred. Such costs are classified as research and development expenses in the accompanying consolidat ed statements of income .
Impairments of Other Intangible Assets and Goodwill	Impairments of Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect a risk factor, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount .
Investments in Non-Consolidated Affiliates	Investments in non-consolidated affiliates During 2021, the Company’s Automotive segment invested $5,200 for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. During 2021, the Company’s Automotive segment invested $2,357 for an ownership interest in Forciot Oy (“Forciot”), a technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. In December 2021, the Company committed to make a $5,000 investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten year life of the fund. The Company has not made any contributions to the Autotech Fund III, LP as of December 31, 2021. This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy.
Research and Development Expenses	Research and Development Expenses Research and development activities are expensed as incurred. The Company groups development and prototype costs and related reimbursements in research and development.
Leases	Leases The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 10 years and may include options to extend the lease. Land leases have remaining lease terms that range from 39 to 41 years and some which specify that the end of the lease term is at the discretion of the lessee. We do not have lease arrangements with related parties. The Company determines whether a contractual arrangement is or contains a lease at inception. Leases that are operating in nature are recognized in Operating lease right-of-use assets, Current lease liabilities and Non-current lease liabilities in the accompanying consolidated balance sheets. Gentherm is not currently party to any leases that qualify as financing leases. Lease liabilities are measured initially at the present value of the sum of the future minimum rental payments at the commencement date of the lease. Lease payments that will vary in the future due to changes in facts and circumstances are excluded from the calculation of rental payments, unless those variable payments are based on an index or rate. Rental payments are discounted using an incremental borrowing rate, unless there is a rate implicit in the lease agreement. The incremental borrowing rate is based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). Judgement is used to assess the importance of risk factor inputs during the computation of the Company’s credit rating. For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease right-of-use assets are measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentive received, and initial direct costs incurred, as applicable. Periods covered by an option to extend the lease are initially included in the measurement of an operating lease right-of-use asset and lease liability only when it is reasonably certain we will exercise the option. Gentherm’s lease agreements do not contain residual value guarantees or impose restrictions or covenants on the Company. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income.
Income Taxes	Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2021 and 2020, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognize s the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in I ncome tax expense.
Derivative Financial Instruments - Hedge Accounting	Derivative Financial Instruments – Hedge Accounting The Company accounts for its derivative financial instruments as cash flow hedges. For derivative contracts which are designated as a cash flow hedge, the effective portion of the change in the fair value of the derivative contract is recorded to Accumulated other comprehensive loss (“AOCI”) in the accompanying consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in AOCI is recorded into earnings in the accompanying consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the accompanying consolidated statements of income under Foreign currency gain (loss) for foreign currency derivatives, and cost of goods sold for commodity derivatives. These hedging transactions and the respective correlations meet the requirements for hedge accounting.
Earnings Per Share	Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the respective period. The Company’s diluted earnings per share give effect to all potential shares of common stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of common stock equivalents.
Stock Based Compensation	Stock Based Compensation Share based payments that involve the issuance of common stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the consolidated financial statements as compensation expense based upon the fair value on the date of grant. Share based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Income Taxes In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". This ASU simplifies the accounting for income taxes by removing certain exceptions previously included in the guidance. In addition, the ASU amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 as of January 1, 2021 and there was no significant impact on its financial statements and related disclosures as a result
Recently Issued Accounting Pronouncements Not Yet Adopted	Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting”. ASU 2020-04 provides practical expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments in this update apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued as a result of reference rate reform. These amendments are not applicable to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. In January 2021, the FASB subsequently issued ASU 2021-01, “Reference Rate Reform (Topic 848): Scope” to clarify that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. ASU 2020-04 and ASU 2021-01 are effective as of March 12, 2020 through December 31, 2022 and may be applied retrospectively to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020, or on a prospective basis to new modifications from any date within an interim period that includes or is subsequent to the date of the issuance of a final update, up to the date that financial statements are available to be issued. Upon adoption of this standard, the Company does not expect it to have a material impact to the Company’s financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Estimated Useful Lives of Property and Equipment	Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years
Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets	Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 10 years Product development costs 5 to 10 years Trade names Indefinite

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2021
Restructuring And Related Activities [Abstract]
Summary of Restructuring Expense by Reportable Segment	Restructuring expense by reporting segment for the years ended December 31, 2021, 2020 and 2019 was as follows: Year Ended December 31, 2021 2020 2019 Automotive $ 2,793 $ 5,075 $ 9,353 Medical — 112 1,838 Corporate 1,064 616 1,728 Total $ 3,857 $ 5,803 $ 12,919
Summary of Restructuring Activity for All Restructuring Initiatives	The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2021 and 2020: Employee Separation Costs Other Related Costs Total Balance at December 31, 2019 $ 5,994 $ 71 $ 6,065 Additions, charged to restructuring expenses 6,932 1,271 8,203 Change in estimate (2,382 ) (18 ) (2,400 ) Cash payments (5,052 ) (757 ) (5,809 ) Non-cash utilization — (687 ) (687 ) Currency translation and other 135 120 255 Balance at December 31, 2020 $ 5,627 $ — $ 5,627 Additions, charged to restructuring expenses 2,406 1,927 4,333 Change in estimate (214 ) (262 ) (476 ) Cash payments (6,129 ) (1,709 ) (7,838 ) Non-cash utilization — (218 ) (218 ) Currency translation and other (196 ) 262 66 Balance at December 31, 2021 $ 1,494 $ — $ 1,494

Details of Certain Financial _2

Details of Certain Financial Statement Components (Tables)	12 Months Ended
	Dec. 31, 2021
Financial Statement Components [Abstract]
Details of Certain Financial Statement Components	December 31, 2021 2020 Inventory: Raw materials, net of reserve $ 96,426 $ 68,362 Work in process, net of reserve 9,495 8,247 Finished goods, net of reserve 53,556 45,792 Total inventory, net $ 159,477 $ 122,401 Other current assets: Notes receivable $ 13,033 $ 19,200 Income tax and other tax receivable 10,681 10,514 Billable tooling 3,778 4,831 Prepaid expenses 3,407 3,930 Other 1,876 2,713 Total other current assets $ 32,775 $ 41,188 Property and equipment: Machinery and equipment $ 155,463 $ 142,833 Buildings and improvements 100,788 99,011 Information technology 33,060 30,338 Production tooling 25,180 22,783 Leasehold improvements 11,445 11,762 Construction in progress 14,506 8,968 Total property and equipment 340,442 315,695 Less: accumulated depreciation (185,172 ) (163,114 ) Total property and equipment, net $ 155,270 $ 152,581 Other current liabilities: Accrued employee liabilities $ 28,818 $ 26,612 Liabilities from discounts and rebates 27,343 22,910 Income tax and other taxes payable 17,068 14,714 Restructuring 1,494 5,627 Accrued warranty 1,916 2,391 Other 5,554 9,155 Total other current liabilities $ 82,193 $ 81,409

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment	Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2021 and 2020 were as follows: Automotive Medical Total December 31, 2019 $ 36,938 $ 27,634 $ 64,572 Exchange rate impact 2,557 895 3,452 Balance as of December 31, 2020 $ 39,495 $ 28,529 $ 68,024 Acquisition of B&E — 976 976 Exchange rate impact (2,166 ) (801 ) (2,967 ) Balance as of December 31, 2021 $ 37,329 $ 28,704 $ 66,033
Summary of Other Intangible Assets and Accumulated Amortization Balances	Other intangible assets and accumulated amortization balances as of December 31, 2021 and 2020 were as follows: Gross Carrying Value Accumulated Amortization Net Carrying Value Definite-lived: Customer relationships $ 90,448 $ (64,105 ) $ 26,343 Technology 29,464 (24,487 ) 4,977 Product development costs 20,329 (19,772 ) 557 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2021 $ 145,918 $ (108,364 ) $ 37,554 Gross Carrying Value Accumulated Amortization Net Carrying Value Definite-lived: Customer relationships $ 97,815 $ (63,432 ) $ 34,383 Technology 30,615 (24,075 ) 6,540 Product development costs 22,164 (21,336 ) 828 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2020 $ 155,264 $ (108,843 ) $ 46,421
Summary of Estimate of Other Intangible Asset Amortization	An estimate of other intangible asset amortization by year, is as follows: 2022 $ 7,929 2023 $ 4,752 2024 $ 3,692 2025 $ 3,678 2026 $ 3,261

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Components of Lease Expense and Other Information	Components of lease expense for the years ended December Year Ended December 31, 2021 2020 2019 Lease cost: Operating lease cost $ 8,227 $ 6,773 $ 5,899 Short-term lease cost 1,941 1,834 3,444 Sublease income (163 ) (158 ) (128 ) Total lease cost $ 10,005 $ 8,449 $ 9,215 Other information related to leases is as follows: Year Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 7,685 $ 6,817 Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 2,379 $ 25,161 December 31, 2021 December 31, 2020 Weighted average remaining lease term: Operating leases 6.9 years 5.4 years Weighted average discount rate: Operating leases 4.53 % 4.65 %
Summary of Operating Leases Under all Non-Cancellable Operating Leases	A summary of operating leases as of December 31, 2021, under all non-cancellable operating leases with terms exceeding one year is as follows: . 2022 $ 6,541 2023 4,664 2024 4,200 2025 3,783 2026 2,945 2027 or later 7,538 Total future minimum lease payments 29,671 Less imputed interest (4,213 ) Total $ 25,458

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Summary of Company's Debt	The following table summarizes the Company’s debt as of December 31, 2021 and 2020: December 31, 2021 2020 Interest Rate Principal Balance Interest Rate Principal Balance Amended Credit Agreement: U.S. Revolving Note (U.S. Dollar denominations) 1.35 % $ 35,000 1.65 % $ 171,500 U.S. Revolving Note (Euro denominations) — — 1.50 % 14,684 DEG Vietnam Loan 5.21 % 3,750 5.21 % 6,250 Total debt 38,750 192,434 Current maturities (2,500 ) (2,500 ) Long-term debt, less current maturities $ 36,250 $ 189,934
Principal Maturities of Debt	The scheduled principal maturities of our debt as of December 31, 2021 were as follows: DEG Vietnam Note U.S. Revolving Note Total 2022 $ 2,500 $ — $ 2,500 2023 1,250 — 1,250 2024 — 35,000 35,000 Total $ 3,750 $ 35,000 $ 38,750

Pension and Other Post Retire_2

Pension and Other Post Retirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]
Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans	The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2021, 2020 and 2019 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2021 2020 2019 2021 2020 2019 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 42 85 127 91 88 147 Expected return on plan assets — — — (120 ) (121 ) (126 ) Amortization of prior service cost and actuarial loss 26 7 — 133 124 72 Net periodic benefit cost $ 68 $ 92 $ 127 $ 104 $ 91 $ 93 Assumptions: Discount rate 1.20 % 2.40 % 3.65 % 1.08 % 1.06 % 1.06 % Long-term return on assets N/A N/A N/A 2.90 % 3.10 % 3.10 %
Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification	A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2021 and 2020 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2021 2020 2021 2020 Change in projected benefit obligation: Balance at beginning of year $ 3,847 $ 3,871 $ 8,934 $ 8,353 Interest cost 42 85 91 88 Paid pension distributions (342 ) (342 ) (310 ) (294 ) Actuarial (gain) loss (101 ) 233 9 40 Exchange rate impact — — (622 ) 747 Balance at end of year $ 3,446 $ 3,847 $ 8,102 $ 8,934 Change in plan assets: Balance at beginning of year — — 4,276 3,825 Actual return on plan assets — — 98 96 Contributions — — 310 294 Paid pension distributions — — (310 ) (294 ) Exchange rate impact — — (305 ) 355 Balance at end of year $ — $ — $ 4,069 $ 4,276 Underfunded Status $ (3,446 ) $ (3,847 ) $ (4,033 ) $ (4,658 ) Balance sheet classification: Other current liabilities $ (342 ) $ (342 ) $ (306 ) $ — Pension benefit obligation (3,104 ) (3,505 ) (3,727 ) (4,658 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 575 701 3,288 3,644 Assumptions: Discount rate 1.80 % 1.20 % 1.25 % 1.08 %
Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost	Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2022 are as follows: U.S Plan German Plan Actuarial losses $ 21 $ 124
Summary of Accumulated Benefit Obligations	The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2021 2020 2021 2020 Accumulated benefit obligation $ 3,446 $ 3,847 $ 8,102 $ 8,934
Schedule of Future Expected Pension Payments	The schedule of future expected pension payments is as follows: Projected Pension Benefit Payments Year U.S Plan German Plan 2022 $ 342 $ 306 2023 342 316 2024 342 309 2025 342 301 2026 342 292 2027-2031 1,710 2,988 Total $ 3,420 $ 4,512

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Reconciliation of Changes in Accrued Warranty Costs	The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2021 2020 Balance at beginning of year $ 2,391 $ 4,596 Warranty claims paid (2,164 ) (2,598 ) Warranty expense for products shipped during the current period 1,813 1,223 Adjustments to warranty estimates from prior periods (73 ) (893 ) Adjustments due to currency translation (51 ) 63 Balance at end of year $ 1,916 $ 2,391

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings per Share and Weighted Average Shares Outstanding Used in Calculating Basic and Diluted Earnings per Share	The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2021 2020 2019 Net income $ 93,434 $ 59,690 $ 48,866 Basic weighted average shares of Common Stock outstanding 33,085,732 32,666,025 33,120,076 Dilutive effect of stock options, restricted stock awards and restricted stock units 423,988 362,079 177,513 Diluted weighted average shares of Common Stock outstanding 33,509,720 33,028,104 33,297,589 Basic earnings per share $ 2.82 $ 1.83 $ 1.48 Diluted earnings per share $ 2.79 $ 1.81 $ 1.47
Common Stock Issuable upon Exercise of Certain Stock Options	The following table represents Common Stock issuable upon the exercise of certain stock options that have been excluded from the diluted earnings calculation because the effect of their inclusion would be anti-dilutive. Year Ended December 31, 2021 2020 2019 Anti-dilutive securities share impact — 12,000 214,000

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet	Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2021 is as follows: Asset Derivatives Liability Derivatives Hedge Designation Fair Value Hierarchy Balance Sheet Location Fair Value Balance Sheet Location Fair Value Net Asset/ (Liabilities) Foreign currency derivatives Cash flow hedge Level 2 Other current assets $ 294 Other current liabilities $ — $ 294 Commodity hedges Cash flow hedge Level 2 Other current assets $ 6 Other current liabilities $ — $ 6 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2020 is as follows: Asset Derivatives Liability Derivatives Hedge Designation Fair Value Hierarchy Balance Sheet Location Fair Value Balance Sheet Location Fair Value Net Asset/ (Liabilities) Foreign currency derivatives Cash flow hedge Level 2 Other current assets $ 1,513 Other current liabilities $ — $ 1,513 Commodity hedges Cash flow hedge Level 2 Other current assets $ — Other current liabilities $ — $ —
Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income	Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2021 2020 2019 Foreign currency derivatives Cost of sales $ 1,609 $ (1,629 ) $ 1,976 Other comprehensive (loss) income (1,217 ) 272 1,151 Foreign currency loss — (118 ) (46 ) Total foreign currency derivatives $ 392 $ (1,475 ) $ 3,081 Commodity derivatives Cost of sales $ 14 $ — $ — Other comprehensive (loss) income 6 — — Total commodity derivatives $ 20 $ — $ —

Reclassifications Out of Accu_2

Reclassifications Out of Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Income (Loss)	Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the years ended December 31, 2021, 2020 and 2019 are as follows: Defined Benefit Pension Plans Foreign Currency Translation Adjustments Commodity Hedge Derivatives Foreign Currency Hedge Derivatives Total Balance at December 31, 2020 $ (3,451 ) $ (12,637 ) $ — $ 1,106 $ (14,982 ) Other comprehensive income (loss) before reclassifications 512 (21,274 ) 20 392 (20,350 ) Income tax effect of other comprehensive income (loss) before reclassifications (71 ) (277 ) (4 ) (85 ) (437 ) Amounts reclassified from accumulated other comprehensive loss into net income 159 — (14 ) a (1,609 ) a (1,464 ) Income taxes reclassified into net income (42 ) — 3 350 311 Net current period other comprehensive income (loss) 558 (21,551 ) 5 (952 ) (21,940 ) Balance at December 31, 2021 $ (2,893 ) $ (34,188 ) $ 5 $ 154 $ (36,922 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. Defined Benefit Pension Plans Foreign Currency Translation Adjustments Foreign Currency Hedge Derivatives Total Balance at December 31, 2019 $ (3,371 ) $ (39,879 ) $ 895 $ (42,355 ) Other comprehensive (loss) income before reclassifications (328 ) 27,147 (1,751 ) 25,068 Income tax effect of other comprehensive (loss) income before reclassifications 117 95 381 593 Amounts reclassified from accumulated other comprehensive loss into net income 131 — 2,023 a 2,154 Income taxes reclassified into net income — — (442 ) (442 ) Net current period other comprehensive (loss) income (80 ) 27,242 211 27,373 Balance at December 31, 2020 $ (3,451 ) $ (12,637 ) $ 1,106 $ (14,982 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. Defined Benefit Pension Plans Foreign Currency Translation Adjustments Foreign Currency Hedge Derivatives Total Balance at December 31, 2018 $ (2,339 ) $ (37,157 ) $ (4 ) $ (39,500 ) Other comprehensive (loss) income before reclassifications (1,264 ) (2,329 ) 2,259 (1,334 ) Income tax effect of other comprehensive (loss) income before reclassifications 232 (393 ) (493 ) (654 ) Amounts reclassified from accumulated other comprehensive loss into net income — — (1,108 ) a (1,108 ) Income taxes reclassified into net income — — 241 241 Net current period other comprehensive (loss) income (1,032 ) (2,722 ) 899 (2,855 ) Balance at December 31, 2019 $ (3,371 ) $ (39,879 ) $ 895 $ (42,355 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income.

Accounting for Stock Based Co_2

Accounting for Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Recognized and Unrecognized Stock-based Compensation Expense	The total recognized and unrecognized stock-based compensation expense is as follows: Stock-Based Compensation Expense 2021 2020 2019 Unrecognized Stock-Based Compensation Expense at December 31, 2021 Options $ 482 $ 836 $ 885 $ - Restricted Shares 1,198 1,495 1,600 309 Restricted Stock Units 4,594 3,137 1,751 7,423 Performance Based Units 5,535 3,361 2,017 8,572 Stock Appreciation Rights 2,721 5,494 2,336 - Total Stock-Based Compensation $ 14,530 $ 14,323 $ 8,589 $ 16,304
Summary of Stock Option Activity	The following table summarizes stock option activity during the years ended December 31, 2021, 2020 and 2019: Options Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2018 1,653,000 $ 38.53 4.28 $ 3,610 Granted — — Exercised (428,250 ) 38.66 Forfeited (355,750 ) 39.99 Outstanding at December 31, 2019 869,000 $ 37.87 3.51 $ 5,172 Granted — — Exercised (434,250 ) 38.12 Forfeited (6,750 ) 38.05 Outstanding at December 31, 2020 428,000 $ 37.61 3.20 $ 11,815 Granted — — Exercised (215,250 ) 38.46 Forfeited (6,000 ) 38.05 Outstanding at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375 Exercisable at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375
Restricted Stock Activity	The following table summarizes restricted stock activity during the years ended December 31, 2021, 2020 and 2019: Unvested Restricted Shares Shares Weighted-Average Grant Date Fair Value Outstanding at December 31, 2018 136,566 $ 37.16 Granted 19,920 40.16 Vested (91,566 ) 37.09 Forfeited (30,000 ) 38.05 Outstanding at December 31, 2019 34,920 $ 38.31 Granted 32,406 39.96 Vested (32,420 ) 38.33 Forfeited — — Outstanding at December 31, 2020 34,906 $ 39.82 Granted 13,742 70.18 Vested (37,272 ) 41.70 Forfeited — — Outstanding at December 31, 2021 11,376 $ 70.33
Summary of Performance Stock Unit Activity	The following table summarizes performance stock unit activity during the years ended December 31, 2021, 2020 and 2019: Unvested Performance Stock Units Relative TSR Target Shares Weighted-Average Grant Date Fair Value ROIC Target Shares Weighted-Average Grant Date Fair Value Adjusted EBITDA Target Shares Weighted-Average Grant Date Fair Value Total Outstanding at December 31, 2018 64,785 $ 62.45 64,792 $ 42.53 — $ — 129,577 Granted 56,380 57.39 56,375 41.51 — — 112,755 Vested — — — — — — — Forfeited (26,124 ) 53.98 (26,128 ) 39.41 — — (52,252 ) Outstanding at December 31, 2019 95,041 $ 61.77 95,039 $ 42.78 — $ — 190,080 Granted 77,967 49.25 77,967 33.72 — — 155,934 Vested — — — — — — — Forfeited (15,090 ) 56.84 (15,090 ) 39.96 — — (30,180 ) Outstanding at December 31, 2020 157,918 $ 56.06 157,916 $ 38.58 — $ — 315,834 Granted 20,626 118.08 40,580 78.98 39,930 79.49 101,136 Performance Adjustment 30,828 69.18 (30,830 ) 44.92 — — (2 ) Vested (61,656 ) 69.18 — — — — (61,656 ) Forfeited (16,148 ) 61.10 (17,374 ) 44.32 (2,454 ) 79.49 (35,976 ) Outstanding at December 31, 2021 131,568 $ 62.09 150,292 $ 47.52 37,476 $ 79.49 319,336
SARs Activity	The following table summarizes SARs activity during the years ended December 31, 2021, 2020 and 2019: Stock Appreciation Rights Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2018 988,100 $ 40.61 3.57 $ 2,064 Granted — — Exercised (179,500 ) 32.84 Forfeited (254,350 ) 42.63 Outstanding at December 31, 2019 554,250 $ 39.41 2.84 $ 2,981 Granted — — Exercised (342,150 ) 38.22 Forfeited (40,500 ) 44.39 Outstanding at December 31, 2020 171,600 $ 40.60 2.44 $ 4,224 Granted — — Exercised (116,000 ) 40.34 Forfeited — — Outstanding at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544 Exercisable at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544
RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted Stock Activity	The following table summarizes restricted stock unit activity during the years ended December 31, 2021, 2020 and 2019: Unvested Restricted Stock Units Time Vesting Shares Weighted-Average Grant Date Fair Value Outstanding at December 31, 2018 86,392 $ 42.53 Granted 107,391 40.99 Vested (23,956 ) 42.62 Forfeited (28,086 ) 39.88 Outstanding at December 31, 2019 141,741 $ 42.16 Granted 132,864 34.41 Vested (50,953 ) 42.13 Forfeited (14,747 ) 39.16 Outstanding at December 31, 2020 208,905 $ 37.26 Granted 93,539 79.79 Vested (88,296 ) 38.49 Forfeited (20,522 ) 48.76 Outstanding at December 31, 2021 193,626 $ 56.02

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Earnings Before Income Taxes	The income tax provisions were calculated based upon the following components of earnings before income tax for the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Earnings before income tax: Domestic $ (4,547 ) $ (11,374 ) $ 74,531 Foreign 118,399 92,930 (15,380 ) Earnings before income tax $ 113,852 $ 81,556 $ 59,151
Provision for Income Taxes	The components of the provision for income taxes for the years ended December 31, 2021, 2020 and 2019 are summarized as follows: Year Ended December 31, 2021 2020 2019 Current income tax expense: Federal $ 1,944 $ 784 $ 262 State and local 234 83 94 Foreign 18,390 20,150 17,672 Total current income tax expense $ 20,568 21,017 18,028 Deferred income tax (benefit) expense: Federal (4,400 ) (2,302 ) (2,490 ) State and local (91 ) 32 (1 ) Foreign 4,341 3,119 (5,252 ) Total deferred (benefit) income tax expense (150 ) 849 (7,743 ) Total income tax expense $ 20,418 $ 21,866 $ 10,285
Deferred Tax Assets and Deferred Tax Liabilities	The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2021 and 2020: December 31, 2021 2020 Deferred tax assets: Net operating losses $ 25,610 $ 22,658 Intangible assets 21,179 29,145 Research and development credits 9,736 10,773 Property and equipment 7,071 7,426 Valuation reserves and accrued liabilities 7,333 7,131 Capitalized Research and Development Costs 9,018 Stock compensation 3,832 4,200 Defined benefit obligation 1,466 1,974 Inventory 1,914 1,571 Other credits 10,158 12,068 Unrealized foreign currency exchange loss — 1,431 Other 146 64 Total deferred tax asset 97,463 98,441 Valuation allowance (16,090 ) (17,197 ) Deferred tax liabilities: Unrealized foreign currency exchange gains $ (2,488 ) $ — Undistributed profits of subsidiary (6,676 ) (5,727 ) Property and equipment (2,420 ) (2,758 ) Other (1,428 ) (572 ) Total deferred tax liability (13,012 ) (9,057 ) Net deferred tax asset $ 68,361 $ 72,187
Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate	Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2021, 2020 and 2019 are as follows: Year Ended December 31, 2021 2020 2019 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance (1.2 )% (0.4 )% 11.5 % Effect of different tax rates of foreign jurisdictions (5.2 )% (4.7 )% (24.8 )% US taxes on foreign income, net of taxes paid credit 2.0 % 2.5 % 4.3 % Tax credits & deductions related to R&D (2.3 )% (3.8 )% (3.6 )% Non-deductible expenses 1.7 % 2.1 % 3.4 % Other foreign, state and local taxes 1.6 % 1.4 % 1.7 % Tax effects of intercompany transfers 0.6 % 1.4 % 1.5 % Undistributed profit of subsidiaries 1.0 % 0.9 % 1.2 % Stock Option Compensation (2.0 )% (0.4 )% 1.0 % Audit Settlements and Statute Expirations 0.0 % 3.9 % 0.6 % Other 0.7 % 2.9 % (0.4 )% Effective rate 17.9 % 26.8 % 17.4 %
Net Operating Loss Carryforwards	The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2021 Years of Expiration U.S. state income tax $ 67,795 2022-2041 Foreign $ 199,153 Never
Reconciliation of Unrecognized Tax Benefits	The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2021 2020 2019 Balance at beginning of year $ 4,967 $ 3,795 $ 2,819 Additions based on tax position related to current year 1,105 1,489 661 Additions based on tax position related to prior year 160 179 352 Reductions from settlements and statute of limitation expiration (312 ) (650 ) — Effect of foreign currency translation (255 ) 154 (37 ) Balance at end of year $ 5,665 $ 4,967 $ 3,795

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss)	The tables below present segment information about the reported product revenues and operating income of the Company for years ended December 31, 2021, 2020 and 2019. With the exception of goodwill, asset information by segment is not reported since the Company does not manage assets at a segment level. Automotive Medical Corporate Total 2021: Product revenues $ 1,004,633 $ 41,517 $ — $ 1,046,150 Depreciation and amortization 35,389 2,460 931 38,780 Operating income (loss) 162,994 (1,829 ) (46,159 ) 115,006 2020: Product revenues $ 869,998 $ 43,100 $ — $ 913,098 Depreciation and amortization 37,662 2,366 1,086 41,114 Operating income (loss) 138,410 971 (50,164 ) 89,217 2019: Product revenues $ 920,225 $ 51,459 $ — $ 971,684 Depreciation and amortization 40,923 1,621 1,702 44,246 Operating income (loss) 141,206 (5,735 ) (51,211 ) 84,260
Segment Information About Reported Segment Product Revenues by Product Category	Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2021, 2020 and 2019 are as follows: Year Ended December 31, 2021 2020 2019 Climate Control Seat $ 393,816 $ 342,550 $ 359,355 Seat Heaters 270,054 249,665 284,174 Steering Wheel Heaters 102,496 76,272 65,426 Automotive Cables 84,114 73,997 88,031 Battery Performance Solutions 69,594 50,901 41,498 Electronics 51,648 53,238 47,542 Other Automotive 32,911 23,375 34,199 Subtotal Automotive segment 1,004,633 869,998 920,225 Medical 41,517 43,100 36,860 GPT — — 11,181 CSZ-IC — — 3,418 Subtotal Medical segment 41,517 43,100 51,459 Total Company $ 1,046,150 $ 913,098 $ 971,684
Product Revenues Information by Geographic Area	Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2021, 2020 and 2019 is as follows: Year Ended December 31, 2021 2020 2019 United States $ 404,466 $ 377,577 $ 440,316 China 142,816 101,039 71,461 South Korea 93,516 88,745 63,339 Germany 66,929 58,536 81,315 Japan 63,527 57,785 76,197 Romania 51,367 33,147 26,213 Other 223,529 196,269 212,843 Total Non-U.S. 641,684 535,521 531,368 Total Company $ 1,046,150 $ 913,098 $ 971,684
Percentage of Total Product Revenues Generated from Customers	The table below lists the percentage of total product revenues generated from sales to customers which contributed 10% or more to the Company’s total consolidated product revenue for the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Lear 15 % 15 % 16 % Adient 15 % 14 % 15 %
Schedule of Property and Equipment, Net by Geographic Area	Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2021 and 2020 is as follows: December 31, Property and equipment, net 2021 2020 North Macedonia $ 32,682 $ 36,925 China 25,411 20,375 Mexico 20,296 16,034 Vietnam 19,876 21,080 United States 19,222 19,011 Germany 16,174 15,641 Ukraine 9,539 9,034 Hungary 8,995 10,079 Other 3,075 4,402 Total $ 155,270 $ 152,581

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)Segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Basis Of Presentation And Accounting Policies [Line Items]
Number of reportable segments | Segment	2
capitalized costs to obtain contract	$ 1,946	$ 1,805
Amortization of capitalized costs into product revenues	174	263
Cash and cash equivalents	190,606	268,345
Allowance for doubtful accounts	1,399	1,161
Depreciation expense	29,622	31,037	$ 33,639
Investment amount	$ 5,200
Operating lease, description	The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles.
Operating lease, existence of option to extend	true
Operating lease, options to extend	Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 10 years and may include options to extend the lease.
Forciot Oy | Gentherm Automotive Segment
Basis Of Presentation And Accounting Policies [Line Items]
Investment amount	$ 2,357
Autotech Fund III, L.P.
Basis Of Presentation And Accounting Policies [Line Items]
Investment commitment	$ 5,000
Capital contribution description	As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten year life of the fund.
Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Reimbursable tooling capitalized within prepaid expenses and other current assets	$ 3,778	$ 4,831
Concentration of Credit Risk | Accounts receivable | Lear
Basis Of Presentation And Accounting Policies [Line Items]
Concentration risk percentage	18.00%	18.00%
Concentration of Credit Risk | Accounts receivable | Adient
Basis Of Presentation And Accounting Policies [Line Items]
Concentration risk percentage	22.00%	18.00%
Foreign Jurisdictions
Basis Of Presentation And Accounting Policies [Line Items]
Cash and cash equivalents	$ 161,496	$ 106,598
Minimum
Basis Of Presentation And Accounting Policies [Line Items]
Expected period of costs to be realized to recognize assets	1 year
Operating lease, term of contract	1 year
Minimum | Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Property plant and equipment, estimated useful life	2 years
Minimum | Ground
Basis Of Presentation And Accounting Policies [Line Items]
Operating lease, term of contract	39 years
Maximum
Basis Of Presentation And Accounting Policies [Line Items]
Ownership interest	20.00%
Original maturities of highly liquid investments	90 days
Operating lease, term of contract	10 years
Maximum | Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Property plant and equipment, estimated useful life	10 years
Maximum | Ground
Basis Of Presentation And Accounting Policies [Line Items]
Operating lease, term of contract	41 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2021
Plant and Equipment
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	10 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	Term of lease
Minimum | Buildings and Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	1 year
Minimum | Production Tooling
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	2 years
Minimum | Information Technology
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	1 year
Maximum | Buildings and Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	30 years
Maximum | Production Tooling
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	10 years
Maximum | Information Technology
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets (Detail)	12 Months Ended
	Dec. 31, 2021
Customer Relationships | Minimum
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets useful life	8 years
Customer Relationships | Maximum
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets useful life	15 years
Technology | Minimum
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets useful life	5 years
Technology | Maximum
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets useful life	10 years
Product Development Costs | Minimum
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets useful life	5 years
Product Development Costs | Maximum
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets useful life	10 years

Acquisitions and Divestitures -

Acquisitions and Divestitures - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 01, 2021	Apr. 01, 2019	Feb. 01, 2019	Dec. 31, 2019
Business Acquisition [Line Items]
Asset impairment charges				$ 21,206
Pre-tax gain (loss) on sale of business				(1,587)
GPT
Business Acquisition [Line Items]
Asset impairment charges				21,206
CSZ-IC
Business Acquisition [Line Items]
Total cash proceeds			$ 47,500
Pre-tax gain (loss) on sale of business				4,298
Stihler Electronic Gmb H
Business Acquisition [Line Items]
Net assets acquired		$ 15,476
Business combination future contingent consideration milestone payment		$ 653
Beckmann & Egle Industrieelektronik GmbH
Business Acquisition [Line Items]
Medical business segment unit amount acquired	$ 2,827
GPT
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business				$ (5,885)

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 3,857,000	$ 5,803,000	$ 12,919,000
Impairment loss			21,206,000
Restructuring and related activities, description	Actions under the Plan are expected to be substantially completed by the first half of 2022
Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 10,105,000
Restructuring reserve accelerated depreciation		1,019,000
Other restructuring costs	1,665,000
Restructuring reserve accelerated depreciation			2,087,000
Restructuring expenses remains accrued	943,000
Employee Separation Costs | Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	1,303,000	(832,000)	4,863,000
Employee Separation Costs | Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	889,000	5,382,000	3,193,000
Other Restructuring | Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	0	$ 234,000	$ 2,776,000
Maximum
Restructuring Cost And Reserve [Line Items]
Restructuring and related cost expected total cost	$ 1,000,000

Restructuring - Summary of Rest

Restructuring - Summary of Restructuring Expense by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 3,857	$ 5,803	$ 12,919
Operating Segments | Automotive Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	2,793	5,075	9,353
Operating Segments | Medical Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses		112	1,838
Operating Segments | Corporate Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 1,064	$ 616	$ 1,728

Restructuring - Summary of Re_2

Restructuring - Summary of Restructuring Activity for All Restructuring Initiatives (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	$ 5,627	$ 6,065
Additions, charged to restructuring expenses	4,333	8,203
Change in estimate	(476)	(2,400)
Cash payments	(7,838)	(5,809)
Non-cash utilization	(218)	(687)
Currency translation and other	66	255
Balance, end of period	1,494	5,627
Employee Separation Costs
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	5,627	5,994
Additions, charged to restructuring expenses	2,406	6,932
Change in estimate	(214)	(2,382)
Cash payments	(6,129)	(5,052)
Currency translation and other	(196)	135
Balance, end of period	1,494	5,627
Other Restructuring
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period		71
Additions, charged to restructuring expenses	1,927	1,271
Change in estimate	(262)	(18)
Cash payments	(1,709)	(757)
Non-cash utilization	(218)	(687)
Currency translation and other	$ 262	$ 120

Details of Certain Financial _3

Details of Certain Financial Statement Components (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory:
Raw materials, net of reserve	$ 96,426	$ 68,362
Work in process, net of reserve	9,495	8,247
Finished goods, net of reserve	53,556	45,792
Total inventory, net	159,477	122,401
Other current assets:
Notes receivable	13,033	19,200
Income tax and other tax receivable	10,681	10,514
Billable tooling	3,778	4,831
Prepaid expenses	3,407	3,930
Other	1,876	2,713
Total other current assets	32,775	41,188
Property and equipment:
Machinery and equipment	155,463	142,833
Buildings and improvements	100,788	99,011
Information technology	33,060	30,338
Production tooling	25,180	22,783
Leasehold improvements	11,445	11,762
Construction in progress	14,506	8,968
Total property and equipment	340,442	315,695
Less: accumulated depreciation	(185,172)	(163,114)
Total property and equipment, net	155,270	152,581
Other current liabilities:
Accrued employee liabilities	28,818	26,612
Liabilities from discounts and rebates	27,343	22,910
Income tax and other taxes payable	17,068	14,714
Restructuring	1,494	5,627
Accrued warranty	1,916	2,391	$ 4,596
Other	5,554	9,155
Total other current liabilities	$ 82,193	$ 81,409

Goodwill and Other Intangible_2

Goodwill and Other Intangibles - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 19, 2020	Feb. 28, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			$ 37,554	$ 46,421
Gain on sale of intangible assets				1,978
Other intangible assets			8,821	9,226	$ 10,068
Customer Relationship
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			26,343	34,383
Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			4,977	$ 6,540
Patents and Intellectual Property
Goodwill And Other Intangible Assets [Line Items]
Proceeds from sale of intangible assets	$ 2,055
Patents and Intellectual Property | Other Income
Goodwill And Other Intangible Assets [Line Items]
Gain on sale of intangible assets	$ 1,978
Beckmann & Egle Industrieelektronik GmbH | Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			$ 976
Acquired intangible assets useful life			7 years
Development Stage Technology Company
Goodwill And Other Intangible Assets [Line Items]
Automotive patents and technology acquired		$ 3,141
Defensive intangible assets, useful life		6 years

Goodwill and Other Intangible_3

Goodwill and Other Intangibles - Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Line Items]
Balance, beginning of period	$ 68,024
Balance, end of period	66,033	$ 68,024
Operating Segments
Goodwill [Line Items]
Balance, beginning of period	68,024	64,572
Acquisition of B&E	976
Exchange rate impact	(2,967)	3,452
Balance, end of period	66,033	68,024
Automotive Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	39,495	36,938
Exchange rate impact	(2,166)	2,557
Balance, end of period	37,329	39,495
Medical Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	28,529	27,634
Acquisition of B&E	976
Exchange rate impact	(801)	895
Balance, end of period	$ 28,704	$ 28,529

Goodwill and Other Intangible_4

Goodwill and Other Intangibles - Summary of Other Intangible Assets and Accumulated Amortization Balances (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Intangible Assets [Line Items]
Gross Carrying Value	$ 145,918	$ 155,264
Accumulated Amortization	(108,364)	(108,843)
Net Carrying Value	37,554	46,421
Net Carrying Value	37,554	46,421
Customer Relationships
Intangible Assets [Line Items]
Gross Carrying Value	90,448	97,815
Accumulated Amortization	(64,105)	(63,432)
Net Carrying Value	26,343	34,383
Technology
Intangible Assets [Line Items]
Gross Carrying Value	29,464	30,615
Accumulated Amortization	(24,487)	(24,075)
Net Carrying Value	4,977	6,540
Product Development Costs
Intangible Assets [Line Items]
Gross Carrying Value	20,329	22,164
Accumulated Amortization	(19,772)	(21,336)
Net Carrying Value	557	828
Software Development
Intangible Assets [Line Items]
Gross Carrying Value	1,007
Net Carrying Value	1,007
Tradenames
Intangible Assets [Line Items]
Net Carrying Value	$ 4,670	$ 4,670

Goodwill and Other Intangible_5

Goodwill and Other Intangibles - Summary of Estimate of Other Intangible Asset Amortization (Detail) $ in Thousands	Dec. 31, 2021USD ($)
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2022	$ 7,929
2023	4,752
2024	3,692
2025	3,678
2026	$ 3,261

Leases - Components of Lease Ex

Leases - Components of Lease Expense and Other Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Lease cost:
Operating lease cost	$ 8,227	$ 6,773	$ 5,899
Short-term lease cost	1,941	1,834	3,444
Sublease income	(163)	(158)	(128)
Total lease cost	10,005	8,449	$ 9,215
Operating cash flows for operating leases	7,685	6,817
Right-of-use lease assets obtained in exchange for lease obligations, Operating leases	$ 2,379	$ 25,161
Weighted-average remaining lease term, Operating leases	6 years 10 months 24 days	5 years 4 months 24 days
Weighted-average discount rate, Operating leases	4.53%	4.65%

Leases - Summary of Operating L

Leases - Summary of Operating Leases Under all Non-Cancellable Operating Leases (Detail) $ in Thousands	Dec. 31, 2021USD ($)
Leases [Abstract]
2022	$ 6,541
2023	4,664
2024	4,200
2025	3,783
2026	2,945
2027 or later	7,538
Total future minimum lease payments	29,671
Less imputed interest	(4,213)
Total	$ 25,458

Summary of Company's Debt (Deta

Summary of Company's Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total debt	$ 38,750	$ 192,434
Current maturities	(2,500)	(2,500)
Long-term debt, less current maturities	$ 36,250	$ 189,934
U.S. Revolving Note (U.S. Dollar Denominations)
Debt Instrument [Line Items]
Interest Rate	1.35%	1.65%
Total debt	$ 35,000	$ 171,500
U.S. Revolving Note (Euro Denominations)
Debt Instrument [Line Items]
Interest Rate		1.50%
Total debt		$ 14,684
DEG Vietnam Loan
Debt Instrument [Line Items]
Interest Rate	5.21%	5.21%
Total debt	$ 3,750	$ 6,250

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Jun. 27, 2019	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Debt Instrument [Line Items]
Maximum percentage of stock of non US subsidiaries pledge to secure obligation			66.00%
Federal Funds Rate | Minimum
Debt Instrument [Line Items]
Interest rate			0.50%
Federal Funds Rate | Maximum
Debt Instrument [Line Items]
Interest rate			0.07%
London Interbank Offered Rate
Debt Instrument [Line Items]
Interest rate			0.10%
United State Bank Of America Credit Facility
Debt Instrument [Line Items]
Interest rate			3.25%
Euro Currency Rate Loans
Debt Instrument [Line Items]
Interest rate			1.00%
Euro Currency Rate Loans | Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate			1.25%
Euro Currency Rate Loans | Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate			2.25%
Base Rate Loans | Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate			0.25%
Base Rate Loans | Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate			1.25%
DEG Vietnam Loan
Debt Instrument [Line Items]
Semi-annual principal payments earliest date			2017-11
Semi-annual principal payments latest date			2023-05
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit, repayment amount		$ 169,546,000
Revolving Credit Facility | Revolving Note (U.S. Dollar)
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 475,000,000
Line of credit, outstanding amount			$ 35,000,000
Debt maturity date	Jun. 27, 2024
Increase in maximum borrowing capacity					$ 169,546,000
Remaining borrowing capacity			440,000,000
Revolving Credit Facility | Revolving Note (U.S. Dollar) | Letters of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity			15,000,000
Line of credit, outstanding amount			0	$ 0
Revolving Credit Facility | Revolving Note (U.S. Dollar) | Swing Line Loans
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 40,000,000

Principal Maturities of Debt (D

Principal Maturities of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt maturing in 2022	$ 2,500
Debt maturing in 2023	1,250
Debt maturing in 2024	35,000
Total debt	38,750	$ 192,434
DEG Vietnam Loan
Debt Instrument [Line Items]
Debt maturing in 2022	2,500
Debt maturing in 2023	1,250
Total debt	3,750	$ 6,250
US and Euro Denominated Revolving Note
Debt Instrument [Line Items]
Debt maturing in 2024	35,000
Total debt	$ 35,000

Pension and Other Post Retire_3

Pension and Other Post Retirement Benefit Plans - Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
United States
Net periodic benefit cost:
Interest cost	$ 42	$ 85	$ 127
Amortization of prior service cost and actuarial loss	26	7
Net periodic benefit cost	$ 68	$ 92	$ 127
Assumptions:
Discount rate	1.20%	2.40%	3.65%
German Plan
Net periodic benefit cost:
Interest cost	$ 91	$ 88	$ 147
Expected return on plan assets	(120)	(121)	(126)
Amortization of prior service cost and actuarial loss	133	124	72
Net periodic benefit cost	$ 104	$ 91	$ 93
Assumptions:
Discount rate	1.08%	1.06%	1.06%
Long-term return on assets	2.90%	3.10%	3.10%

Pension and Other Post Retire_4

Pension and Other Post Retirement Benefit Plans - Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance sheet classification:
Pension benefit obligation	$ (6,832)	$ (8,163)
United States
Change in projected benefit obligation:
Balance at beginning of year	3,847	3,871
Interest cost	42	85	$ 127
Paid pension distributions	(342)	(342)
Actuarial (gain) loss	(101)	233
Balance at end of year	3,446	3,847	3,871
Change in plan assets:
Underfunded Status	(3,446)	(3,847)
Balance sheet classification:
Other current liabilities	(342)	(342)
Pension benefit obligation	(3,104)	(3,505)
Accumulated other comprehensive loss (pre-tax):
Actuarial losses	$ 575	$ 701
Discount rate	1.80%	1.20%
German Plan
Change in projected benefit obligation:
Balance at beginning of year	$ 8,934	$ 8,353
Interest cost	91	88	147
Paid pension distributions	(310)	(294)
Actuarial (gain) loss	9	40
Exchange rate impact	(622)	747
Balance at end of year	8,102	8,934	8,353
Change in plan assets:
Balance at beginning of year	4,276	3,825
Actual return on plan assets	98	96
Contributions	310	294
Paid pension distributions	(310)	(294)
Exchange rate impact	(305)	355
Balance at end of year	4,069	4,276	$ 3,825
Underfunded Status	(4,033)	(4,658)
Balance sheet classification:
Other current liabilities	(306)
Pension benefit obligation	(3,727)	(4,658)
Accumulated other comprehensive loss (pre-tax):
Actuarial losses	$ 3,288	$ 3,644
Discount rate	1.25%	1.08%

Pension and Other Post Retire_5

Pension and Other Post Retirement Benefit Plans - Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
United States
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses		$ 575	$ 701
German Plan
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses		$ 3,288	$ 3,644
Scenario Forecast | United States
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ 21
Scenario Forecast | German Plan
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ 124

Pension and Other Post Retire_6

Pension and Other Post Retirement Benefit Plans - Summary of Accumulated Benefit Obligations (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
United States
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 3,446	$ 3,847
German Plan
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 8,102	$ 8,934

Pension and Other Post Retire_7

Pension and Other Post Retirement Benefit Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
401(k) Plan
Defined Benefit Plan Disclosure [Line Items]
Cost recognized for contributions to defined contribution plan	$ 1,724,000	$ 1,275,000	$ 1,384,000
United States
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, expected employer contribution in next fiscal year	0
German Plan
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, expected employer contribution in next fiscal year	$ 0

Pension and Other Post Retire_8

Pension and Other Post Retirement Benefit Plans - Schedule of Future Expected Pension Payments (Detail) - Gentherm GmbH $ in Thousands	Dec. 31, 2021USD ($)
United States
Defined Benefit Plan Disclosure [Line Items]
2022	$ 342
2023	342
2024	342
2025	342
2026	342
2027-2031	1,710
Total projected pension benefit payments	3,420
German Plan
Defined Benefit Plan Disclosure [Line Items]
2022	306
2023	316
2024	309
2025	301
2026	292
2027-2031	2,988
Total projected pension benefit payments	$ 4,512

Commitments and Contingencies -

Commitments and Contingencies - Reconciliation of Changes in Accrued Warranty Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Loss Contingency [Abstract]
Balance at beginning of year	$ 2,391	$ 4,596
Warranty claims paid	(2,164)	(2,598)
Warranty expense for products shipped during the current period	1,813	1,223
Adjustments to warranty estimates from prior periods	(73)	(893)
Adjustments due to currency translation	(51)	63
Balance at end of year	$ 1,916	$ 2,391

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)Agreement
Loss Contingencies [Line Items]
Number of agreements expire in 2022 | Agreement	0
Labor agreements expiration period	2022
Labor Agreements
Loss Contingencies [Line Items]
Percentage of workforce as members of industrial trade unions	23.00%
Capital Expenditures
Loss Contingencies [Line Items]
Commitments	$ 5,388
Semiconductor Chips
Loss Contingencies [Line Items]
Commitments	$ 24,457
Commitment period	24 months

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net income	$ 93,434	$ 59,690	$ 48,866
Basic weighted average shares of Common Stock outstanding	33,085,732	32,666,025	33,120,076
Dilutive effect of stock options, restricted stock awards and restricted stock units	423,988	362,079	177,513
Diluted weighted average shares of Common Stock outstanding	33,509,720	33,028,104	33,297,589
Basic earnings per share	$ 2.82	$ 1.83	$ 1.48
Diluted earnings per share	$ 2.79	$ 1.81	$ 1.47
Anti-dilutive securities share impact		12,000	214,000

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Derivative [Line Items]
Maximum length of time to hedges exposure to foreign currency exchange risk		15 months
Receivables transferred		$ 0
Maximum
Derivative [Line Items]
Aggregate purchases of accounts receivable	$ 41,300,000
Foreign Currency Derivatives
Derivative [Line Items]
Notional Value		13,974,000	$ 13,299,000
Copper Commodity Swap Contracts
Derivative [Line Items]
Notional Value		309,000	0
Interest Rate Swap
Derivative [Line Items]
Hedge Ineffectiveness Incurred		$ 0	$ 0

Information Related to Recurrin

Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet (Detail) - Fair Value, Inputs, Level 2 - Designated as Hedging Instrument - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Foreign Currency Derivatives
Derivatives Fair Value [Line Items]
Net Asset/ (Liabilities)	$ 294	$ 1,513
Foreign Currency Derivatives | Other Current Assets
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	294	$ 1,513
Commodity Hedges
Derivatives Fair Value [Line Items]
Net Asset/ (Liabilities)	6
Commodity Hedges | Other Current Assets
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 6

Information Related to Effect o

Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Gain (loss) on derivatives	$ 392	$ (1,475)	$ 3,081
Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Gain (loss) on derivatives	20
Other comprehensive (loss) income | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Gain (loss) on derivatives	(1,217)	272	1,151
Other comprehensive (loss) income | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Gain (loss) on derivatives	6
Cost of sales | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Gain (loss) on derivatives	1,609	(1,629)	1,976
Cost of sales | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Gain (loss) on derivatives	$ 14
Foreign currency loss | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Gain (loss) on derivatives		$ (118)	$ (46)

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	Jul. 01, 2021	Dec. 31, 2021	Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value		$ 38,750,000	$ 192,434,000
DEG Vietnam Loan
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value		3,750,000	6,250,000
Fair value		3,778,000	6,360,000
Beckmann & Egle Industrieelektronik GmbH
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Medical business segment unit amount acquired	$ 2,827,000
Fair Value, Recurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value		0	0
Financial liabilities, fair value		0	0
Fair Value, Nonrecurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value		0	0
Financial liabilities, fair value		$ 0	$ 0

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Common Stock, shares authorized	55,000,000	55,000,000
Preferred stock, shares authorized	4,991,000
Common Stock, shares issued	33,008,185	32,921,341
Common Stock, shares outstanding	33,008,185	32,921,341
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Shares repurchased	20,000
Shares repurchased average price paid per share	$ 83.44
Remaining authorized repurchase amount	$ 130,000
2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program period		3 years
Stock repurchase program expiration date		Dec. 15, 2023
Maximum
Class Of Stock [Line Items]
Shares issued	59,991,000
Maximum | 2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program, authorized to repurchase amount		150,000

Schedule of Reclassification Ad

Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		$ (14,982)	$ (42,355)	$ (39,500)
Other comprehensive income (loss) before reclassifications		(20,350)	25,068	(1,334)
Income tax effect of other comprehensive income (loss) before reclassifications		(437)	593	(654)
Amounts reclassified from accumulated other comprehensive loss into net income		(1,464)	2,154	(1,108)
Income taxes reclassified into net income		311	(442)	241
Other comprehensive (loss) income, net of tax		(21,940)	27,373	(2,855)
Ending Balance		(36,922)	(14,982)	(42,355)
Defined Benefit Pension Plans
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		(3,451)	(3,371)	(2,339)
Other comprehensive income (loss) before reclassifications		512	(328)	(1,264)
Income tax effect of other comprehensive income (loss) before reclassifications		(71)	117	232
Amounts reclassified from accumulated other comprehensive loss into net income		159	131
Income taxes reclassified into net income		(42)
Other comprehensive (loss) income, net of tax		558	(80)	(1,032)
Ending Balance		(2,893)	(3,451)	(3,371)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		(12,637)	(39,879)	(37,157)
Other comprehensive income (loss) before reclassifications		(21,274)	27,147	(2,329)
Income tax effect of other comprehensive income (loss) before reclassifications		(277)	95	(393)
Other comprehensive (loss) income, net of tax		(21,551)	27,242	(2,722)
Ending Balance		(34,188)	(12,637)	(39,879)
Commodity Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Other comprehensive income (loss) before reclassifications		20
Income tax effect of other comprehensive income (loss) before reclassifications		(4)
Amounts reclassified from accumulated other comprehensive loss into net income		(14)
Income taxes reclassified into net income		3
Other comprehensive (loss) income, net of tax		5
Ending Balance		5
Foreign Currency Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		1,106	895	(4)
Other comprehensive income (loss) before reclassifications		392	(1,751)	2,259
Income tax effect of other comprehensive income (loss) before reclassifications		(85)	381	(493)
Amounts reclassified from accumulated other comprehensive loss into net income	[1]	(1,609)	2,023	(1,108)
Income taxes reclassified into net income		350	(442)	241
Other comprehensive (loss) income, net of tax		(952)	211	899
Ending Balance		$ 154	$ 1,106	$ 895
[1]	The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales.  See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income.

Accounting for Stock Based Co_3

Accounting for Stock Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	May 21, 2020	May 19, 2017	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	May 16, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance based restricted stock units outstanding			11,376	34,906	34,920	136,566
Shareholder Return Award Performance Measurement Period			3 years
Deferred tax benefit			$ 2,725	$ 3,002	$ 1,573
Granted, Shares			0	0	0	0
Total intrinsic value of options exercised			$ 8,269	$ 5,317	$ 1,681
Total fair value of restricted shares vested			$ 1,554	$ 1,499	$ 3,697
Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance based restricted stock units outstanding			319,336	315,834	190,080	129,577
These awards vesting period			3 years
Awards vesting condition			Company’s achievement of either a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year a target three year cumulative Adjusted EBITDA (“Adjusted EBITDA”), as defined in the award agreement, or the Company’s relative total shareholder return (“TSR”), as defined in the award agreement, during a specific three-year measurement period.
Stock option achieving minimum threshold			50.00%
Stock option achieving maximum threshold			200.00%
Total intrinsic value of stock units vested			$ 4,265	$ 0	$ 0
RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of stock units vested			$ 3,398	$ 2,214	$ 1,000
Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted, Shares			0	0	0	0
Total intrinsic value of options exercised			$ 4,301	$ 4,164	$ 1,588
Employee and Consultants | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period			3 years
Employee and Consultants | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period			4 years
Director
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period			1 year
2013 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for grant			2,739,534
Number of shares authorized for grant							3,500,000
Number of increased shares available for grant	2,450,000	2,000,000

Accounting for Stock Based Co_4

Accounting for Stock Based Compensation - Summary of Recognized and Unrecognized Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 14,530	$ 14,323	$ 8,589
Unrecognized Stock-Based Compensation Expense	16,304
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	482	836	885
Restricted Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	1,198	1,495	1,600
Unrecognized Stock-Based Compensation Expense	309
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	4,594	3,137	1,751
Unrecognized Stock-Based Compensation Expense	7,423
Performance Based Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	5,535	3,361	2,017
Unrecognized Stock-Based Compensation Expense	8,572
Stock Appreciation Rights
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 2,721	$ 5,494	$ 2,336

Accounting for Stock Based Co_5

Accounting for Stock Based Compensation - Summarizes Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options Outstanding, beginning balance, Shares	428,000	869,000	1,653,000
Granted, Shares	0	0	0	0
Exercised, Shares	(215,250)	(434,250)	(428,250)
Forfeited, Shares	(6,000)	(6,750)	(355,750)
Stock Options Outstanding, ending balance, Shares	206,750	428,000	869,000	1,653,000
Stock Options Exercisable, Shares	206,750
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 37.61	$ 37.87	$ 38.53
Exercised, Weighted-Average Exercise Price	38.46	38.12	38.66
Forfeited, Weighted-Average Exercise Price	38.05	38.05	39.99
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	36.72	$ 37.61	$ 37.87	$ 38.53
Exercisable, Weighted-Average Exercise Price	$ 36.72
Stock Options Outstanding, Weighted-Average Remaining Contractual Term	2 years 7 months 6 days	3 years 2 months 12 days	3 years 6 months 3 days	4 years 3 months 10 days
Exercisable, Weighted-Average Remaining Contractual Term	2 years 7 months 6 days
Stock Options Outstanding, Aggregate Intrinsic Value	$ 10,375	$ 11,815	$ 5,172	$ 3,610
Exercisable, Aggregate Intrinsic Value	$ 10,375

Accounting for Stock Based Co_6

Accounting for Stock Based Compensation - Summarizes Restricted Stock Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Outstanding at beginning of period, Shares	34,906	34,920	136,566
Granted, Shares	13,742	32,406	19,920
Vested, Shares	(37,272)	(32,420)	(91,566)
Forfeited, Shares			(30,000)
Outstanding at end of period, Shares	11,376	34,906	34,920
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 39.82	$ 38.31	$ 37.16
Granted, Weighted-Average Grant Date Fair Value	70.18	39.96	40.16
Vested, Weighted-Average Grant Date Fair Value	41.70	38.33	37.09
Forfeited, Weighted-Average Grant Date Fair Value			38.05
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 70.33	$ 39.82	$ 38.31

Accounting for Stock Based Co_7

Accounting for Stock Based Compensation - Summarizes Restricted Stock Unit Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	34,906	34,920	136,566
Granted, Shares	13,742	32,406	19,920
Vested, Shares	(37,272)	(32,420)	(91,566)
Forfeited, Shares			(30,000)
Outstanding at end of period, Shares	11,376	34,906	34,920
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 39.82	$ 38.31	$ 37.16
Granted, Weighted-Average Grant Date Fair Value	70.18	39.96	40.16
Vested, Weighted-Average Grant Date Fair Value	41.70	38.33	37.09
Forfeited, Weighted-Average Grant Date Fair Value			38.05
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 70.33	$ 39.82	$ 38.31
RSU | Time Vesting Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	208,905	141,741	86,392
Granted, Shares	93,539	132,864	107,391
Vested, Shares	(88,296)	(50,953)	(23,956)
Forfeited, Shares	(20,522)	(14,747)	(28,086)
Outstanding at end of period, Shares	193,626	208,905	141,741
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 37.26	$ 42.16	$ 42.53
Granted, Weighted-Average Grant Date Fair Value	79.79	34.41	40.99
Vested, Weighted-Average Grant Date Fair Value	38.49	42.13	42.62
Forfeited, Weighted-Average Grant Date Fair Value	48.76	39.16	39.88
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 56.02	$ 37.26	$ 42.16

Accounting for Stock Based Co_8

Accounting for Stock Based Compensation - Summarizes Performance Stock Units Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	34,906	34,920	136,566
Granted, Shares	13,742	32,406	19,920
Vested, Shares	(37,272)	(32,420)	(91,566)
Forfeited, Shares			(30,000)
Outstanding at end of period, Shares	11,376	34,906	34,920
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 39.82	$ 38.31	$ 37.16
Granted, Weighted-Average Grant Date Fair Value	70.18	39.96	40.16
Vested, Weighted-Average Grant Date Fair Value	41.70	38.33	37.09
Forfeited, Weighted-Average Grant Date Fair Value			38.05
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 70.33	$ 39.82	$ 38.31
Performance Based Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	315,834	190,080	129,577
Granted, Shares	101,136	155,934	112,755
Performance Adjustment, Shares	(2)
Vested, Shares	(61,656)
Forfeited, Shares	(35,976)	(30,180)	(52,252)
Outstanding at end of period, Shares	319,336	315,834	190,080
Performance Based Units | Relative TSR Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	157,918	95,041	64,785
Granted, Shares	20,626	77,967	56,380
Performance Adjustment, Shares	30,828
Vested, Shares	(61,656)
Forfeited, Shares	(16,148)	(15,090)	(26,124)
Outstanding at end of period, Shares	131,568	157,918	95,041
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 56.06	$ 61.77	$ 62.45
Granted, Weighted-Average Grant Date Fair Value	118.08	49.25	57.39
Performance Adjustment, Weighted-Average Grant Date Fair Value	69.18
Vested, Weighted-Average Grant Date Fair Value	69.18
Forfeited, Weighted-Average Grant Date Fair Value	61.10	56.84	53.98
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 62.09	$ 56.06	$ 61.77
Performance Based Units | ROIC Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	157,916	95,039	64,792
Granted, Shares	40,580	77,967	56,375
Performance Adjustment, Shares	(30,830)
Forfeited, Shares	(17,374)	(15,090)	(26,128)
Outstanding at end of period, Shares	150,292	157,916	95,039
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 38.58	$ 42.78	$ 42.53
Granted, Weighted-Average Grant Date Fair Value	78.98	33.72	41.51
Performance Adjustment, Weighted-Average Grant Date Fair Value	44.92
Forfeited, Weighted-Average Grant Date Fair Value	44.32	39.96	39.41
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 47.52	$ 38.58	$ 42.78
Performance Based Units | Adjusted EBITDA Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted, Shares	39,930
Forfeited, Shares	(2,454)
Outstanding at end of period, Shares	37,476
Granted, Weighted-Average Grant Date Fair Value	$ 79.49
Forfeited, Weighted-Average Grant Date Fair Value	79.49
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 79.49

Accounting for Stock Based Co_9

Accounting for Stock Based Compensation - Summarizes Stock Appreciation Rights (SARs) Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, beginning balance, Shares	428,000	869,000	1,653,000
Granted, Shares	0	0	0	0
Exercised, Shares	(215,250)	(434,250)	(428,250)
Forfeited, Shares	(6,000)	(6,750)	(355,750)
Stock Options Outstanding, ending balance, Shares	206,750	428,000	869,000	1,653,000
Exercisable, Ending Balance	206,750
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 37.61	$ 37.87	$ 38.53
Exercised, Weighted-Average Exercise Price	38.46	38.12	38.66
Forfeited, Weighted-Average Exercise Price	38.05	38.05	39.99
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	36.72	$ 37.61	$ 37.87	$ 38.53
Exercisable, Weighted Average Exercise Price	$ 36.72
Stock Options Outstanding, Weighted-Average Remaining Contractual Term	2 years 7 months 6 days	3 years 2 months 12 days	3 years 6 months 3 days	4 years 3 months 10 days
Exercisable, Weighted-Average Remaining Contractual Term	2 years 7 months 6 days
Outstanding, Aggregate Intrinsic Value	$ 10,375	$ 11,815	$ 5,172	$ 3,610
Exercisable, Aggregate Intrinsic Value	$ 10,375
Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, beginning balance, Shares	171,600	554,250	988,100
Granted, Shares	0	0	0	0
Exercised, Shares	(116,000)	(342,150)	(179,500)
Forfeited, Shares		(40,500)	(254,350)
Stock Options Outstanding, ending balance, Shares	55,600	171,600	554,250	988,100
Exercisable, Ending Balance	55,600
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 40.60	$ 39.41	$ 40.61
Exercised, Weighted-Average Exercise Price	40.34	38.22	32.84
Forfeited, Weighted-Average Exercise Price		44.39	42.63
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	41.15	$ 40.60	$ 39.41	$ 40.61
Exercisable, Weighted Average Exercise Price	$ 41.15
Stock Options Outstanding, Weighted-Average Remaining Contractual Term	1 year 3 months 10 days	2 years 5 months 8 days	2 years 10 months 2 days	3 years 6 months 25 days
Exercisable, Weighted-Average Remaining Contractual Term	1 year 3 months 10 days
Outstanding, Aggregate Intrinsic Value	$ 2,544	$ 4,224	$ 2,981	$ 2,064
Exercisable, Aggregate Intrinsic Value	$ 2,544

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Taxes [Line Items]
Undistributed earnings offsetting with dividend received deduction percent	100.00%
Total unrecognized tax benefits	$ 5,665	$ 4,967	$ 3,795	$ 2,819
U.S. State | Earliest Tax Year
Income Taxes [Line Items]
Operating loss carryforward, year of expiration	2022
U.S. State | Latest Tax Year
Income Taxes [Line Items]
Operating loss carryforward, year of expiration	2041
Non-U.S. Subsidiaries
Income Taxes [Line Items]
Operating loss carryforward, amount	$ 199,153
Net operating loss carryforward, year of expiration	no expiration date
Foreign Jurisdictions
Income Taxes [Line Items]
Income tax holiday, description	The Company currently benefits from tax holidays in various non-U.S. jurisdictions with expiration dates from 2024 – 2025.

Income Taxes - Earnings Before

Income Taxes - Earnings Before Income Taxes and Tax Provisions - (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings before income tax:
Domestic	$ (4,547)	$ (11,374)	$ 74,531
Foreign	118,399	92,930	(15,380)
Earnings before income tax	$ 113,852	$ 81,556	$ 59,151

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current income tax expense:
Federal	$ 1,944	$ 784	$ 262
State and local	234	83	94
Foreign	18,390	20,150	17,672
Total current income tax expense	20,568	21,017	18,028
Deferred income tax (benefit) expense:
Federal	(4,400)	(2,302)	(2,490)
State and local	(91)	32	(1)
Foreign	4,341	3,119	(5,252)
Total deferred (benefit) income tax expense	(150)	849	(7,743)
Total income tax expense	$ 20,418	$ 21,866	$ 10,285

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating losses	$ 25,610	$ 22,658
Intangible assets	21,179	29,145
Research and development credits	9,736	10,773
Property and equipment	7,071	7,426
Valuation reserves and accrued liabilities	7,333	7,131
Capitalized Research and Development Costs	9,018
Stock compensation	3,832	4,200
Defined benefit obligation	1,466	1,974
Inventory	1,914	1,571
Other credits	10,158	12,068
Unrealized foreign currency exchange loss		1,431
Other	146	64
Total deferred tax asset	97,463	98,441
Valuation allowance	(16,090)	(17,197)
Deferred tax liabilities:
Unrealized foreign currency exchange gains	(2,488)
Undistributed profits of subsidiary	(6,676)	(5,727)
Property and equipment	(2,420)	(2,758)
Other	(1,428)	(572)
Total deferred tax liability	(13,012)	(9,057)
Net deferred tax asset	$ 68,361	$ 72,187

Income Taxes - Reconciliations

Income Taxes - Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Statutory Federal income tax rate	21.00%	21.00%	21.00%
Increase (decrease) resulting from:
Change in valuation allowance	(1.20%)	(0.40%)	11.50%
Effect of different tax rates of foreign jurisdictions	(5.20%)	(4.70%)	(24.80%)
US taxes on foreign income, net of taxes paid credit	2.00%	2.50%	4.30%
Tax credits & deductions related to R&D	(2.30%)	(3.80%)	(3.60%)
Non-deductible expenses	1.70%	2.10%	3.40%
Other foreign, state and local taxes	1.60%	1.40%	1.70%
Tax effects of intercompany transfers	0.60%	1.40%	1.50%
Undistributed profit of subsidiaries	1.00%	0.90%	1.20%
Stock Option Compensation	(2.00%)	(0.40%)	1.00%
Audit Settlements and Statute Expirations	0.00%	3.90%	0.60%
Other	0.70%	2.90%	(0.40%)
Effective rate	17.90%	26.80%	17.40%

Income Taxes - Net Operating Lo

Income Taxes - Net Operating Loss Carryforwards (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
U.S. state income tax
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, amount	$ 67,795
U.S. state income tax | Minimum
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, year of expiration	2022
U.S. state income tax | Maximum
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, year of expiration	2041
Foreign, Indefinite
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, amount	$ 199,153
Operating loss carryforward, year of expiration	Never

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ 4,967	$ 3,795	$ 2,819
Additions based on tax position related to current year	1,105	1,489	661
Additions based on tax position related to prior year	160	179	352
Reductions from settlements and statute of limitation expiration	(312)	(650)
Effect of foreign currency translation	(255)	154	(37)
Balance at end of year	$ 5,665	$ 4,967	$ 3,795

Segment Reporting - Segment Inf

Segment Reporting - Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Product revenues	$ 1,046,150	$ 913,098	$ 971,684
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 38,780	$ 41,114	$ 44,246
Operating income (loss)	115,006	89,217	84,260
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues	$ 1,004,633	$ 869,998	$ 920,225
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 35,389	$ 37,662	$ 40,923
Operating income (loss)	162,994	138,410	141,206
Medical Segments
Segment Reporting Information [Line Items]
Product revenues	$ 41,517	$ 43,100	$ 51,459
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 2,460	$ 2,366	$ 1,621
Operating income (loss)	$ (1,829)	$ 971	$ (5,735)
Corporate Segments
Segment Reporting Information [Line Items]
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 931	$ 1,086	$ 1,702
Operating income (loss)	$ (46,159)	$ (50,164)	$ (51,211)

Segment Reporting - Segment I_2

Segment Reporting - Segment Information About Reported Segment Product Revenues by Product Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Product revenues	$ 1,046,150	$ 913,098	$ 971,684
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues	1,004,633	869,998	920,225
Automotive Segments | Climate Control Seat
Segment Reporting Information [Line Items]
Product revenues	393,816	342,550	359,355
Automotive Segments | Seat Heaters
Segment Reporting Information [Line Items]
Product revenues	270,054	249,665	284,174
Automotive Segments | Steering Wheel Heaters
Segment Reporting Information [Line Items]
Product revenues	102,496	76,272	65,426
Automotive Segments | Automotive Cables
Segment Reporting Information [Line Items]
Product revenues	84,114	73,997	88,031
Automotive Segments | Battery Performance Solutions
Segment Reporting Information [Line Items]
Product revenues	69,594	50,901	41,498
Automotive Segments | Electronics
Segment Reporting Information [Line Items]
Product revenues	51,648	53,238	47,542
Automotive Segments | Other Automotive
Segment Reporting Information [Line Items]
Product revenues	32,911	23,375	34,199
Industrial Segments
Segment Reporting Information [Line Items]
Product revenues	41,517	43,100	51,459
Industrial Segments | Medical
Segment Reporting Information [Line Items]
Product revenues	$ 41,517	$ 43,100	36,860
Industrial Segments | GPT
Segment Reporting Information [Line Items]
Product revenues			11,181
Industrial Segments | CSZ-IC
Segment Reporting Information [Line Items]
Product revenues			$ 3,418

Segment Reporting (Detail)

Segment Reporting (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Product revenues	$ 1,046,150	$ 913,098	$ 971,684
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
United States
Segment Reporting Information [Line Items]
Product revenues	$ 404,466	$ 377,577	$ 440,316
China
Segment Reporting Information [Line Items]
Product revenues	142,816	101,039	71,461
South Korea
Segment Reporting Information [Line Items]
Product revenues	93,516	88,745	63,339
Germany
Segment Reporting Information [Line Items]
Product revenues	66,929	58,536	81,315
Japan
Segment Reporting Information [Line Items]
Product revenues	63,527	57,785	76,197
Romania
Segment Reporting Information [Line Items]
Product revenues	51,367	33,147	26,213
Other
Segment Reporting Information [Line Items]
Product revenues	223,529	196,269	212,843
Non U.S.
Segment Reporting Information [Line Items]
Product revenues	$ 641,684	$ 535,521	$ 531,368

Segment Reporting - Percentage

Segment Reporting - Percentage of Total Product Revenues Generated from Customers (Detail) - Sales Revenue, Net - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Lear
Segment Reporting Information [Line Items]
Total product revenues in percentage	15.00%	15.00%	16.00%
Adient
Segment Reporting Information [Line Items]
Total product revenues in percentage	15.00%	14.00%	15.00%

Segment Reporting - Segment Rep

Segment Reporting - Segment Reporting About Property and Equipment, Net by Geographic Areas (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Property and equipment, net	$ 155,270	$ 152,581
North Macedonia
Segment Reporting Information [Line Items]
Property and equipment, net	32,682	36,925
Vietnam
Segment Reporting Information [Line Items]
Property and equipment, net	19,876	21,080
China
Segment Reporting Information [Line Items]
Property and equipment, net	25,411	20,375
United States
Segment Reporting Information [Line Items]
Property and equipment, net	19,222	19,011
Mexico
Segment Reporting Information [Line Items]
Property and equipment, net	20,296	16,034
Germany
Segment Reporting Information [Line Items]
Property and equipment, net	16,174	15,641
UKRAINE
Segment Reporting Information [Line Items]
Property and equipment, net	9,539	9,034
Hungary
Segment Reporting Information [Line Items]
Property and equipment, net	8,995	10,079
Other
Segment Reporting Information [Line Items]
Property and equipment, net	$ 3,075	$ 4,402

Valuation and Qualifying Acco_2

Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Allowance for Doubtful Accounts
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 1,161	$ 1,193	$ 851
Charged to Costs and Expenses	1,066	1,298	969
Other Activity	(12)	33	(8)
Deductions from Reserves	(816)	(1,363)	(619)
Balance at End of Period	1,399	1,161	1,193
Allowance for Deferred Income Tax Assets
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	17,197	17,316	9,977
Charged to Costs and Expenses	357		7,830
Other Activity	(102)	139	(491)
Deductions from Reserves	(1,362)	(258)
Balance at End of Period	16,090	17,197	17,316
Reserve for Inventory
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	7,141	6,073	6,270
Charged to Costs and Expenses	2,499	1,768	1,679
Other Activity	(134)	214	(56)
Deductions from Reserves	(3,492)	(914)	(1,820)
Balance at End of Period	$ 6,014	$ 7,141	$ 6,073